rasagiline profile

ID Source	ID
PubMed CID	3052776
CHEMBL ID	887
CHEBI ID	63620
SCHEMBL ID	74699
SCHEMBL ID	2029054
MeSH ID	M0100095

Synonym
AC-723
unii-003n66ts6t
hsdb 7699
003n66ts6t ,
nsc 759639
tv 1030
rasagiline [usan:inn]
AKOS015837675
tv-1030
RAS ,
rasagiline ,
chembl887 ,
bdbm10989
(1r)-n-(prop-2-yn-1-yl)-2,3-dihydro-1h-inden-1-amine
DB01367
(r)-n-2-propynyl-1-indanamine
(r)-indan-1-yl-prop-2-ynyl-amine
(1r)-n-propargylindan-1-amine
1-indanamine, n-2-propynyl-, (r)-
1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (1r)
rasagiline [inn]
136236-51-6
nsc-759639
chebi:63620 ,
D08469
rasagiline (usan/inn)
(1r)-n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine
A2916
(r)-n-(prop-2-ynyl)-2,3-dihydro-1h-inden-1-amine;(r)-n-(2-propynyl)-2,3-dihydroinden-1-amine
HMS3264K12
AKOS006271452
(r)-2,3-dihydro-n-2-propynyl-1h-inden-1-amine
nsc759639
pharmakon1600-01502333
(r)-n-(2-propynyl)-2,3-dihydroinden-1-amine
FS-3130
(1r)-n-(prop-2-yn-1-yl)indan-1-amine
rasagiline [hsdb]
rasagiline [who-dd]
1h-inden-1-amine, 2,3-dihydro-n-2-propyn-1-yl-, (1r)-
(r)-(+)-rasagiline
rasagiline [mi]
rasagiline [vandf]
(1r)-2,3-dihydro-n-2-propyn-1-yl-1h-inden-1-amine
rasagiline [usan]
rasagiline [ema epar]
1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (1r)-
rasagiline [orange book]
1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (r)-
AM84542
S5795
gtpl6641
CCG-213034
HY-14605A
SCHEMBL74699
smr002533187
MLS006012042
RUOKEQAAGRXIBM-GFCCVEGCSA-N
n-propargyl-1-(r)aminoindan
SCHEMBL2029054
AB01562963_01
AB01562963_02
DTXSID3041112
sr-00000006359
SR-00000006359-3
HMS3715L12
(r)-n-(prop-2-ynyl)-2,3-dihydro-1h-inden-1-amine
Q420685
1204184-69-9
EN300-150047
HMS3886N03
nsc-789038
nsc789038

Role	Description
EC 1.4.3.4 (monoamine oxidase) inhibitor	An EC 1.4.3.* (oxidoreductase acting on donor CH-NH2 group, oxygen as acceptor) inhibitor that interferes with the action of monoamine oxidase (EC 1.4.3.4).
neuroprotective agent	Any compound that can be used for the treatment of neurodegenerative disorders.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
secondary amine	A compound formally derived from ammonia by replacing two hydrogen atoms by hydrocarbyl groups.
indanes
terminal acetylenic compound	An acetylenic compound which a carbon of the C#C moiety is attached to a hydrogen atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cholinesterase	Homo sapiens (human)	IC50 (µMol)	2.3865	0.0000	1.5599	10.0000	AID1465285; AID1556701
Amine oxidase [flavin-containing] B	Rattus norvegicus (Norway rat)	IC50 (µMol)	3.3422	0.0004	0.7649	12.5000	AID1199581; AID1399984; AID1586574; AID1600694
Amine oxidase [flavin-containing] B	Rattus norvegicus (Norway rat)	Ki	0.1739	0.0008	1.0927	6.0000	AID1192621; AID1192622; AID1796581
Amine oxidase [flavin-containing] A	Rattus norvegicus (Norway rat)	IC50 (µMol)	133.9143	0.0007	1.9798	12.5000	AID1199580; AID1399983; AID1586572
Amine oxidase [flavin-containing] A	Rattus norvegicus (Norway rat)	Ki	0.0142	0.0019	0.5533	4.8000	AID1192621
Amine oxidase [flavin-containing] A	Homo sapiens (human)	IC50 (µMol)	64.8532	0.0000	2.3789	9.7700	AID125558; AID1292320; AID1323962; AID1334743; AID1336724; AID1352195; AID1374197; AID1390035; AID1421879; AID1427512; AID1436076; AID1437168; AID1444065; AID1453105; AID1458405; AID1465287; AID1465302; AID1485915; AID1517859; AID1519692; AID1528913; AID1551696; AID1556700; AID1557173; AID1568798; AID1569980; AID1586573; AID1635482; AID1657150; AID1667262; AID1691660; AID1706696; AID1709260; AID1751716; AID1757198; AID1761631; AID1802599; AID1851411; AID314094; AID706469; AID743813
Amine oxidase [flavin-containing] A	Homo sapiens (human)	Ki	5.1667	0.0019	2.3797	10.0000	AID125561; AID1796578; AID1796579; AID1796581
Acetylcholinesterase	Homo sapiens (human)	IC50 (µMol)	0.0190	0.0000	0.9332	10.0000	AID1465284
Amine oxidase [flavin-containing] B	Homo sapiens (human)	IC50 (µMol)	3.9312	0.0000	1.8914	9.5700	AID126541; AID1292322; AID1323961; AID1334745; AID1336725; AID1352196; AID1374198; AID1390036; AID1421880; AID1427513; AID1436077; AID1437169; AID1444066; AID1453106; AID1456237; AID1458404; AID1465288; AID1465303; AID1485916; AID1517860; AID1519691; AID1528914; AID1532335; AID1532341; AID1551697; AID1556701; AID1557174; AID1568796; AID1569982; AID1586575; AID1635461; AID1639030; AID1657151; AID1667263; AID1691662; AID1704813; AID1705912; AID1706697; AID1709261; AID1740536; AID1751717; AID1754140; AID1754141; AID1757197; AID1761632; AID1802599; AID1851412; AID1872726; AID1907519; AID314095; AID658202; AID706470; AID743812; AID779070
Amine oxidase [flavin-containing] B	Homo sapiens (human)	Ki	2.5246	0.0006	1.7771	10.0000	AID1192621; AID1192622; AID126542; AID1796578; AID1796579; AID1796581; AID254307
5-hydroxytryptamine receptor 6	Homo sapiens (human)	Ki	0.0014	0.0002	0.5229	10.0000	AID1705911
Amine oxidase [flavin-containing] B	Bos taurus (cattle)	Ki	0.5000	0.0540	1.8390	6.0000	AID1796581
Amine oxidase [flavin-containing] B	Mus musculus (house mouse)	Ki	0.5000	0.1000	2.3790	6.0000	AID1796581
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	Cholinesterase	Homo sapiens (human)
learning	Cholinesterase	Homo sapiens (human)
negative regulation of cell population proliferation	Cholinesterase	Homo sapiens (human)
neuroblast differentiation	Cholinesterase	Homo sapiens (human)
peptide hormone processing	Cholinesterase	Homo sapiens (human)
response to alkaloid	Cholinesterase	Homo sapiens (human)
cocaine metabolic process	Cholinesterase	Homo sapiens (human)
negative regulation of synaptic transmission	Cholinesterase	Homo sapiens (human)
response to glucocorticoid	Cholinesterase	Homo sapiens (human)
response to folic acid	Cholinesterase	Homo sapiens (human)
choline metabolic process	Cholinesterase	Homo sapiens (human)
acetylcholine catabolic process	Cholinesterase	Homo sapiens (human)
biogenic amine metabolic process	Amine oxidase [flavin-containing] A	Homo sapiens (human)
positive regulation of signal transduction	Amine oxidase [flavin-containing] A	Homo sapiens (human)
dopamine catabolic process	Amine oxidase [flavin-containing] A	Homo sapiens (human)
acetylcholine catabolic process in synaptic cleft	Acetylcholinesterase	Homo sapiens (human)
regulation of receptor recycling	Acetylcholinesterase	Homo sapiens (human)
osteoblast development	Acetylcholinesterase	Homo sapiens (human)
acetylcholine catabolic process	Acetylcholinesterase	Homo sapiens (human)
cell adhesion	Acetylcholinesterase	Homo sapiens (human)
nervous system development	Acetylcholinesterase	Homo sapiens (human)
synapse assembly	Acetylcholinesterase	Homo sapiens (human)
receptor internalization	Acetylcholinesterase	Homo sapiens (human)
negative regulation of synaptic transmission, cholinergic	Acetylcholinesterase	Homo sapiens (human)
amyloid precursor protein metabolic process	Acetylcholinesterase	Homo sapiens (human)
positive regulation of protein secretion	Acetylcholinesterase	Homo sapiens (human)
retina development in camera-type eye	Acetylcholinesterase	Homo sapiens (human)
acetylcholine receptor signaling pathway	Acetylcholinesterase	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Acetylcholinesterase	Homo sapiens (human)
response to xenobiotic stimulus	Amine oxidase [flavin-containing] B	Homo sapiens (human)
response to toxic substance	Amine oxidase [flavin-containing] B	Homo sapiens (human)
response to aluminum ion	Amine oxidase [flavin-containing] B	Homo sapiens (human)
response to selenium ion	Amine oxidase [flavin-containing] B	Homo sapiens (human)
negative regulation of serotonin secretion	Amine oxidase [flavin-containing] B	Homo sapiens (human)
phenylethylamine catabolic process	Amine oxidase [flavin-containing] B	Homo sapiens (human)
substantia nigra development	Amine oxidase [flavin-containing] B	Homo sapiens (human)
response to lipopolysaccharide	Amine oxidase [flavin-containing] B	Homo sapiens (human)
dopamine catabolic process	Amine oxidase [flavin-containing] B	Homo sapiens (human)
response to ethanol	Amine oxidase [flavin-containing] B	Homo sapiens (human)
positive regulation of dopamine metabolic process	Amine oxidase [flavin-containing] B	Homo sapiens (human)
hydrogen peroxide biosynthetic process	Amine oxidase [flavin-containing] B	Homo sapiens (human)
response to corticosterone	Amine oxidase [flavin-containing] B	Homo sapiens (human)
cerebral cortex cell migration	5-hydroxytryptamine receptor 6	Homo sapiens (human)
positive regulation of TOR signaling	5-hydroxytryptamine receptor 6	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	5-hydroxytryptamine receptor 6	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 6	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 6	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 6	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
amyloid-beta binding	Cholinesterase	Homo sapiens (human)
catalytic activity	Cholinesterase	Homo sapiens (human)
acetylcholinesterase activity	Cholinesterase	Homo sapiens (human)
cholinesterase activity	Cholinesterase	Homo sapiens (human)
protein binding	Cholinesterase	Homo sapiens (human)
hydrolase activity, acting on ester bonds	Cholinesterase	Homo sapiens (human)
enzyme binding	Cholinesterase	Homo sapiens (human)
choline binding	Cholinesterase	Homo sapiens (human)
identical protein binding	Cholinesterase	Homo sapiens (human)
protein binding	Amine oxidase [flavin-containing] A	Homo sapiens (human)
primary amine oxidase activity	Amine oxidase [flavin-containing] A	Homo sapiens (human)
aliphatic amine oxidase activity	Amine oxidase [flavin-containing] A	Homo sapiens (human)
monoamine oxidase activity	Amine oxidase [flavin-containing] A	Homo sapiens (human)
flavin adenine dinucleotide binding	Amine oxidase [flavin-containing] A	Homo sapiens (human)
amyloid-beta binding	Acetylcholinesterase	Homo sapiens (human)
acetylcholinesterase activity	Acetylcholinesterase	Homo sapiens (human)
cholinesterase activity	Acetylcholinesterase	Homo sapiens (human)
protein binding	Acetylcholinesterase	Homo sapiens (human)
collagen binding	Acetylcholinesterase	Homo sapiens (human)
hydrolase activity	Acetylcholinesterase	Homo sapiens (human)
serine hydrolase activity	Acetylcholinesterase	Homo sapiens (human)
acetylcholine binding	Acetylcholinesterase	Homo sapiens (human)
protein homodimerization activity	Acetylcholinesterase	Homo sapiens (human)
laminin binding	Acetylcholinesterase	Homo sapiens (human)
protein binding	Amine oxidase [flavin-containing] B	Homo sapiens (human)
primary amine oxidase activity	Amine oxidase [flavin-containing] B	Homo sapiens (human)
electron transfer activity	Amine oxidase [flavin-containing] B	Homo sapiens (human)
identical protein binding	Amine oxidase [flavin-containing] B	Homo sapiens (human)
aliphatic amine oxidase activity	Amine oxidase [flavin-containing] B	Homo sapiens (human)
monoamine oxidase activity	Amine oxidase [flavin-containing] B	Homo sapiens (human)
flavin adenine dinucleotide binding	Amine oxidase [flavin-containing] B	Homo sapiens (human)
histamine receptor activity	5-hydroxytryptamine receptor 6	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 6	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 6	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 6	Homo sapiens (human)
primary amine oxidase activity	Amine oxidase [flavin-containing] B	Bos taurus (cattle)
aliphatic amine oxidase activity	Amine oxidase [flavin-containing] B	Bos taurus (cattle)
monoamine oxidase activity	Amine oxidase [flavin-containing] B	Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular region	Cholinesterase	Homo sapiens (human)
nuclear envelope lumen	Cholinesterase	Homo sapiens (human)
endoplasmic reticulum lumen	Cholinesterase	Homo sapiens (human)
blood microparticle	Cholinesterase	Homo sapiens (human)
plasma membrane	Cholinesterase	Homo sapiens (human)
extracellular space	Cholinesterase	Homo sapiens (human)
mitochondrion	Amine oxidase [flavin-containing] A	Homo sapiens (human)
mitochondrial outer membrane	Amine oxidase [flavin-containing] A	Homo sapiens (human)
cytosol	Amine oxidase [flavin-containing] A	Homo sapiens (human)
mitochondrion	Amine oxidase [flavin-containing] A	Homo sapiens (human)
extracellular region	Acetylcholinesterase	Homo sapiens (human)
basement membrane	Acetylcholinesterase	Homo sapiens (human)
extracellular space	Acetylcholinesterase	Homo sapiens (human)
nucleus	Acetylcholinesterase	Homo sapiens (human)
Golgi apparatus	Acetylcholinesterase	Homo sapiens (human)
plasma membrane	Acetylcholinesterase	Homo sapiens (human)
cell surface	Acetylcholinesterase	Homo sapiens (human)
membrane	Acetylcholinesterase	Homo sapiens (human)
neuromuscular junction	Acetylcholinesterase	Homo sapiens (human)
synaptic cleft	Acetylcholinesterase	Homo sapiens (human)
synapse	Acetylcholinesterase	Homo sapiens (human)
perinuclear region of cytoplasm	Acetylcholinesterase	Homo sapiens (human)
side of membrane	Acetylcholinesterase	Homo sapiens (human)
mitochondrion	Amine oxidase [flavin-containing] B	Homo sapiens (human)
mitochondrial envelope	Amine oxidase [flavin-containing] B	Homo sapiens (human)
mitochondrial outer membrane	Amine oxidase [flavin-containing] B	Homo sapiens (human)
dendrite	Amine oxidase [flavin-containing] B	Homo sapiens (human)
neuronal cell body	Amine oxidase [flavin-containing] B	Homo sapiens (human)
mitochondrion	Amine oxidase [flavin-containing] B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 6	Homo sapiens (human)
cilium	5-hydroxytryptamine receptor 6	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 6	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 6	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 6	Homo sapiens (human)
mitochondrion	Amine oxidase [flavin-containing] B	Bos taurus (cattle)
mitochondrial outer membrane	Amine oxidase [flavin-containing] B	Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (243)

Assay ID	Title	Year	Journal	Article
AID1796579	MAO A and MAO B Activity Measurements from Article 10.1021/jm0310885: \\Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.\\	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.
AID1796578	MAO A and MAO B Activity Measurements from Article 10.1021/jm0506266: \\Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis.\\	2005	Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26	Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis.
AID1802599	MAO-A/MAO-B Inhibition Assay from Article 10.1016/j.bioorg.2017.02.016: \\Pyridoxine-resveratrol hybrids Mannich base derivatives as novel dual inhibitors of AChE and MAO-B with antioxidant and metal-chelating properties for the treatment of Alzheimer'	2017	Bioorganic chemistry, 04, Volume: 71	Pyridoxine-resveratrol hybrids Mannich base derivatives as novel dual inhibitors of AChE and MAO-B with antioxidant and metal-chelating properties for the treatment of Alzheimer's disease.
AID1796581	MAO Inhibition Assay from Article 10.1074/jbc.M500949200: \\Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors.\\	2005	The Journal of biological chemistry, Apr-22, Volume: 280, Issue:16	Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors.
AID1336724	Inhibition of recombinant human MAO-A expressed in baculovirus infected High 5 insect cells using kynuramine as substrate incubated for 30 mins by spectrofluorometric method	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID126541	Inhibitory concentration towards in human monoamine oxidase B was measured	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.
AID1437169	Inhibition of recombinant human MAO-B using kynuramine as substrate after 30 mins by fluorescence assay	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
AID232415	Ratio of inactive monoamine oxidase A between kinact and Ki	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.
AID1568798	Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate measured after 30 mins by fluorescence based assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID232324	Ratio of A450 decay monoamine oxidase A between kinact and Ki	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.
AID1751722	Time dependent inhibition of recombinant human MAO-B expressed in baculovirus infected BTI-TN- 5B1-4 insect cells assessed as decay in enzyme residual activity at IC80 measured after 30 mins	2021	Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15	Mapping Chromone-3-Phenylcarboxamide Pharmacophore:
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1199587	Neuroprotective activity against rotenone-treated rat PC12 cells assessed as survival at 10 uM after 4 hrs by MTT assay (Rvb = 100 +/- 1.88%)	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1754150	Neuroprotective activity against MPTP-induced C57BL/6J mouse model of Parkinson's disease assessed as decrease in immobility time at 0.2 mg/kg, ip pretreated for 7 consecutive days followed by MPTP challenge and further treated with compound until day 14	2021	Bioorganic & medicinal chemistry letters, 07-01, Volume: 43	Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation.
AID1556700	Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as decrease in H2O2 production using p-tyramine as substrate incubated for 20 mins by horse-radish peroxidase/amplex red-based fluorescence method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Carboxamides vs. methanimines: Crystal structures, binding interactions, photophysical studies, and biological evaluation of (indazole-5-yl)methanimines as monoamine oxidase B and acetylcholinesterase inhibitors.
AID1691660	Inhibition of recombinant human MAO-A	2020	European journal of medicinal chemistry, May-15, Volume: 194	Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease.
AID1519684	Irreversible inhibition of human microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as decay in enzyme residual activity continuously by measuring 4-hydroxyquinoline formation using kynuramine as substrate measured after first	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies.
AID1528915	Selectivity ratio of IC50 for recombinant human microsomal MAOA expressed in baculovirus infected BTI insect cells to IC50 for recombinant human microsomal MAOB expressed in baculovirus infected BTI insect cells
AID1458404	Inhibition of human recombinant microsomal MAOB expressed in baculovirus infected BTI-TN-5B1- 4 cells using p-tyramine as substrate assessed as decrease in H2O2 production after 15 mins by amplex red-based fluorescence assay	2017	Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16	Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?
AID1399984	Inhibition of rat MAOB using benzylamine as substrate pretreated for 1200 secs followed by substrate addition and measured after 3600 secs	2018	Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17	Design, synthesis and biological evaluation of lazabemide derivatives as inhibitors of monoamine oxidase.
AID1437173	Antioxidant activity assessed as trolox equivalent of AAPH radical scavenging activity at 1 uM preincubated for 15 mins followed by AAPH addition measured every min for 90 mins by ORAC-FL assay	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
AID1600694	Inhibition of rat brain MAO-B using [14C]-phenylethylamine as substrate preincubated for 60 mins followed by substrate addition and measured after 20 mins by liquid scintillation counting method	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	Rasagiline derivatives combined with histamine H
AID1352197	Selectivity index, ratio of IC50 for recombinant human MAO-A to IC50 for recombinant human MAO-B	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Design, synthesis and bioevalucation of novel 2,3-dihydro-1H-inden-1-amine derivatives as potent and selective human monoamine oxidase B inhibitors based on rasagiline.
AID1323964	Cytotoxicity against rat PC12 cells assessed as cell survival at 100 uM after 24 hrs by MTT assay relative to control	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22	Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
AID1323966	Neuroprotective activity against 6-OHDA-induced toxicity in rat PC12 cells assessed as cell survival at 20 uM preincubated for 24 hrs followed by 6-OHDA addition measured after 24 hrs by MTT assay relative to control	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22	Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
AID1757197	Inhibition of human recombinant MAO-B by multimode plate reader assay	2021	European journal of medicinal chemistry, Apr-15, Volume: 216	Design, synthesis and evaluation of novel dimethylamino chalcone-O-alkylamines derivatives as potential multifunctional agents against Alzheimer's disease.
AID1453105	Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 30 mins by fluorescence assay	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
AID1851412	Inhibition of human MAO-B assessed as inhibition of H2O2 production using p-tyramine as substrate	2022	Bioorganic & medicinal chemistry letters, 10-15, Volume: 74	Synthesis and human monoamine oxidase inhibitory activity of novel C2-, C3- and C4-substituted phthalonitriles.
AID1519691	Inhibition of human microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as reduction in 4-hydroxyquinoline formation using kynuramine as substrate preincubated with substrate for 10 mins followed by enzyme addition by spectropho	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies.
AID1557170	Inhibition of equine serum BuChE using S-butyrylthiocholine chloride as substrate incubated for 15 mins by Ellman's method	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1754139	Cytotoxicity against human SH-SY5Y cells at 5 to 50 uM after 24 hrs by MTT assay	2021	Bioorganic & medicinal chemistry letters, 07-01, Volume: 43	Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation.
AID1667259	Antioxidant activity assessed as AAPH-induced radical scavenging activity by measuring trolox equivalents for oxygen radical absorbance capacity measured every minute for 90 mins by ORAC-FL assay	2020	Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7	Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1586574	Inhibition of Sprague-Dawley rat liver MAO-B using p-tyramine as substrate preincubated for 15 mins and measured after 45 mins by resorufin-based fluorescence assay	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	(Pyrrolo-pyridin-5-yl)benzamides: BBB permeable monoamine oxidase B inhibitors with neuroprotective effect on cortical neurons.
AID1754143	Cytotoxicity against C57/BL6 mouse BV-2 cells at 5 to 50 uM after 24 hrs by MTT assay	2021	Bioorganic & medicinal chemistry letters, 07-01, Volume: 43	Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation.
AID1754149	Neuroprotective activity against MPTP-induced C57BL/6J mouse model of Parkinson's disease assessed as increase in total distance at 0.2 mg/kg, ip pretreated for 7 consecutive days followed by MPTP challenge and further treated with compound until day 14 b	2021	Bioorganic & medicinal chemistry letters, 07-01, Volume: 43	Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation.
AID1761238	Cytotoxicity against mouse SIM-A9 cells measured after 24 hrs by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease.
AID317112	Activation of ERK1/2 in T20 cells at 10 uM relative to nontreated cells	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	New 1,2,3,4-tetrahydroisoquinoline derivatives as modulators of proteolytic cleavage of amyloid precursor proteins.
AID1421879	Inhibition of human recombinant microsomal MAOA expressed in baculovirus infected BTI-TN-5B1- 4 cells using p-tyramine as substrate assessed as decrease in H2O2 production by amplex red-based fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
AID1751717	Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI-TN- 5B1-4 insect cells using kynuramine as substrate preincubated for 10 mins in presence of substrate followed by enzyme addition and measured every minute for 30 mins by spectro	2021	Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15	Mapping Chromone-3-Phenylcarboxamide Pharmacophore:
AID1458405	Inhibition of human recombinant microsomal MAOA expressed in baculovirus infected BTI-TN-5B1- 4 cells using p-tyramine as substrate assessed as decrease in H2O2 production after 15 mins by amplex red-based fluorescence assay	2017	Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16	Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?
AID1704813	Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI cells using p-tyramine as substrate by fluorometric assay
AID1465288	Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 30 mins by fluorescence assay	2017	Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22	Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
AID1635461	Inhibition of human microsomal MAO-B expressed in recombinant baculovirus infected insect BTI-TN-5B1-4 cells assessed as reduction in H2O2 production using p-tyramine as substrate after 15 mins by fluorescence assay	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.
AID1456237	Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using tyramine as substrate pretreated for 30 mins followed by substrate addition incubated for 30 mins measured at 5 mins interval by horse-radish peroxidase/amplex	2017	European journal of medicinal chemistry, May-05, Volume: 131	MAO enzymes inhibitory activity of new benzimidazole derivatives including hydrazone and propargyl side chains.
AID743813	Inhibition of human recombinant microsomal MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate assessed as production of H2O2 incubated for 15 mins followed by substrate addition measured over 15 mins by fluorimetric a	2013	European journal of medicinal chemistry, May, Volume: 63	Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study.
AID1667263	Inhibition of recombinant human MAOB expressed in baculovirus infected in BTI cells using kynuramine as substrate after 30 mins by fluorescence based assay	2020	Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7	Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
AID1192622	Inhibition of human recombinant soluble MAO-B expressed in Pichia pastoris incubated for 30 mins prior to substrate addition measured after 60 mins by MAO-Glo assay	2015	Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4	Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
AID1427513	Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 30 mins by fluorimetric method	2017	Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6	Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID125726	In vitro inhibitory concentration against Monoamine oxidase A of rat brain homogenates; value ranges from 0.28-0.54	2002	Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24	Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.
AID1374194	Inhibition of cupric ion-mediated amyloid beta (1 to 42) aggregation at 25 uM after 24 hrs by thioflavin T fluorescence assay relative to control	2018	Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5	Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID1336725	Inhibition of recombinant human MAO-B expressed in baculovirus infected High 5 insect cells using kynuramine as substrate incubated for 30 mins by spectrofluorometric method	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1525506	Inhibition of MAO-B in rat brain using [14C]-phenylethylamine as substrate preincubated for 60 mins followed by substrate addition and measured after 30 mins by liquid scintillation counting method	2019	Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20	Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms.
AID1751716	Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI-TN- 5B1-4 insect cells using kynuramine as substrate preincubated for 10 mins in presence of substrate followed by enzyme addition and measured every minute for 30 mins by spectro	2021	Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15	Mapping Chromone-3-Phenylcarboxamide Pharmacophore:
AID1532334	Displacement of [3H]-N-alpha-methylhistamine from human H3 receptor expressed in CHO-K1 cell membranes after 60 mins by microbeta2 scintillation counting analysis	2018	Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24	4-tert-Pentylphenoxyalkyl derivatives - Histamine H
AID743812	Inhibition of human recombinant microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate assessed as production of H2O2 incubated for 15 mins followed by substrate addition measured over 15 mins by fluorimetric a	2013	European journal of medicinal chemistry, May, Volume: 63	Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study.
AID1485917	Selectivity index, ratio of IC50 for recombinant human MAO-A expressed in baculovirus infected BTI insect cells to IC50 for recombinant human MAO-B expressed in baculovirus infected BTI insect cells	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
AID1568796	Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate measured after 30 mins by fluorescence based assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1851414	Selectivity index, ratio of IC50 for inhibition of human MAO-A to IC50 for inhibition of human MAO-B	2022	Bioorganic & medicinal chemistry letters, 10-15, Volume: 74	Synthesis and human monoamine oxidase inhibitory activity of novel C2-, C3- and C4-substituted phthalonitriles.
AID232322	Ratio of A415 rise monoamine oxidase A between kinact and Ki	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.
AID126546	Compound was evaluated for A 450 rise towards monoamine oxidase B enzyme	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.
AID1551697	Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using p-tyramine as substrate preincubated for 60 mins followed by substrate addition and measured after 30 mins by horse-radish peroxidase-coupled amplex red reagent	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease.
AID706468	Selectivity ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB	2012	Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19	Multitarget-directed benzylideneindanone derivatives: anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer's disease.
AID1437168	Inhibition of recombinant human MAO-A using kynuramine as substrate after 30 mins by fluorescence assay	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
AID1551698	Selectivity index, ratio of IC50 for recombinant human MAO-A expressed in baculovirus infected BTI insect cells to IC50 for recombinant human MAO-B expressed in baculovirus infected BTI insect cells	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease.
AID1292322	Inhibition of human recombinant MAO-B using kynuramine as substrate after 30 mins by fluorescence spectrophotometry	2016	Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10	Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID229512	Ratio of IC50 value against MAO-A to that of MAO-B.	2002	Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24	Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.
AID1199578	Selectivity ratio of IC50 for rat brain MAO-A to IC50 for rat brain MAO-B	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
AID1754141	Inhibition of human MAO-A	2021	Bioorganic & medicinal chemistry letters, 07-01, Volume: 43	Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation.
AID317110	Inhibition of monoamino oxidase B from F344/N rat brain cortex	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	New 1,2,3,4-tetrahydroisoquinoline derivatives as modulators of proteolytic cleavage of amyloid precursor proteins.
AID232323	Ratio of A415 rise monoamine oxidase B between kinact and Ki	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.
AID1427512	Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 30 mins by fluorimetric method	2017	Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6	Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID1444065	Irreversible inhibition of human cerebral cortex MAO-A using [14C]-5-hydroxytryptamine creatinine disulphate as substrate pretreated for 60 mins followed by substrate addition after 30 mins by liquid scintillation counting method	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Discovery of highly selective and potent monoamine oxidase B inhibitors: Contribution of additional phenyl rings introduced into 2-aryl-1,3,4-oxadiazin-5(6H)-one.
AID126700	In vitro inhibitory concentration against Monoamine oxidase B of rat brain homogenates; value ranges from 0.0035-0.053	2002	Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24	Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.
AID1519692	Inhibition of human microsomal MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as reduction in 4-hydroxyquinoline formation using kynuramine as substrate preincubated with substrate for 10 mins followed by enzyme addition by spectropho	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies.
AID1528913	Inhibition of recombinant human microsomal MAOA expressed in baculovirus infected BTI insect cells using p-tyramine as substrate preincubated for 15 mins followed by substrate addition and measured over 20 mins by amplex red reagent-based horseradish pero
AID1586575	Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells using p-tyramine as substrate preincubated for 15 mins and measured after 45 mins by resorufin-based fluorescence assay	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	(Pyrrolo-pyridin-5-yl)benzamides: BBB permeable monoamine oxidase B inhibitors with neuroprotective effect on cortical neurons.
AID1352195	Inhibition of recombinant human MAO-A using p-tyramine as substrate preincubated for 15 mins followed by substrate addition measured over 15 mins by Amplex red reagent-based fluorimetric method	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Design, synthesis and bioevalucation of novel 2,3-dihydro-1H-inden-1-amine derivatives as potent and selective human monoamine oxidase B inhibitors based on rasagiline.
AID1192621	Inhibition of human recombinant microsomal MAO-B expressed in Pichia pastoris incubated for 30 mins prior to substrate addition measured after 60 mins by MAO-Glo assay	2015	Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4	Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
AID126542	Binding affinity towards monoamine oxidase B activity was measured using a benzylamine assay	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.
AID635338	Selectivity ratio of Ki for human recombinant MAO-A to Ki for human recombinant MAO-B	2011	Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24	Molecular insights into human monoamine oxidase (MAO) inhibition by 1,4-naphthoquinone: evidences for menadione (vitamin K3) acting as a competitive and reversible inhibitor of MAO.
AID125568	Compound was evaluated for A 450 rise towards monoamine oxidase A enzyme	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.
AID1667262	Inhibition of recombinant human MAOA expressed in baculovirus infected in BTI cells using kynuramine as substrate after 30 mins by fluorescence based assay	2020	Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7	Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
AID254307	Inhibition constant against human recombinant Monoamine oxidase-B	2005	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 15, Issue:20	Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds.
AID1399983	Inhibition of rat MAOA using 5-hydroxytryptamine as substrate pretreated for 1200 secs followed by substrate addition and measured after 3600 secs	2018	Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17	Design, synthesis and biological evaluation of lazabemide derivatives as inhibitors of monoamine oxidase.
AID1336728	Selectivity index, ratio of IC50 for recombinant human MAO-A expressed in baculovirus infected High 5 insect cells to IC50 for recombinant human MAO-B expressed in baculovirus infected High 5 insect cells	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1453106	Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 30 mins by fluorescence assay	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
AID317111	Lipophilicity, log P of the compound	2008	Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4	New 1,2,3,4-tetrahydroisoquinoline derivatives as modulators of proteolytic cleavage of amyloid precursor proteins.
AID1650986	Inhibition of MAO-B in Wistar rat liver using 4-trifluoromethyl benzylamine as substrate preincubated for 20 mins followed by substrate addition measured after 90 mins by microplate reader assay	2020	Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4	Synthesis and biological evaluation of 4-arylcoumarins as potential anti-Alzheimer's disease agents.
AID1374193	Inhibition of self-induced aggregation of amyloid beta (1 to 42) (unknown origin) at 25 uM after 24 hrs by thioflavin T fluorescence method relative to control	2018	Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5	Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID125558	Inhibitory concentration towards in human monoamine oxidase A was measured	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.
AID1851411	Inhibition of human MAO-A assessed as inhibition of H2O2 production using p-tyramine as substrate	2022	Bioorganic & medicinal chemistry letters, 10-15, Volume: 74	Synthesis and human monoamine oxidase inhibitory activity of novel C2-, C3- and C4-substituted phthalonitriles.
AID125570	Compound was evaluated for inactivation for monoamine oxidase A	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.
AID1334746	Selectivity index, ratio of IC50 for human recombinant MAO-A to IC50 for human recombinant MAO-B	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
AID125557	Compound was evaluated for observed mass inactivation in human monoamine oxidase A enzyme	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.
AID314094	Inhibition of MAOA	2008	Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3	Multi-target-directed ligands to combat neurodegenerative diseases.
AID1390035	Inhibition of recombinant human MAO-A using kynuramine as substrate after 30 mins by fluorescence assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID1465284	Inhibition of human erythrocyte AChE using acetylthiocholine chloride as substrate incubated for 15 mins by Ellman's method	2017	Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22	Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
AID1532340	Irreversible inhibition of human MAO-B expressed in baculovirus infected BTI insect cells at IC80 preincubated with compound and p-tyramine for 22 mins followed by p-tyramine increase to 1 mM and measured every minute for 5 hrs by fluorescence assay	2018	Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24	4-tert-Pentylphenoxyalkyl derivatives - Histamine H
AID1517859	Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 30 mins by fluorescence based assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
AID1586573	Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect cells using p-tyramine as substrate preincubated for 15 mins and measured after 45 mins by resorufin-based fluorescence assay	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	(Pyrrolo-pyridin-5-yl)benzamides: BBB permeable monoamine oxidase B inhibitors with neuroprotective effect on cortical neurons.
AID1323963	Selectivity index, ratio of IC50 for recombinant human MAO-A to IC50 for recombinant human MAO-B incubated for 15 mins	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22	Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
AID1706696	Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect cells using p-tyramine as substrate preincubated for 15 mins followed by substrate addition and measured over 20 mins by horse-radish peroxidase/Amplex Red coupled	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Pyrimido[1,2-b]indazole derivatives: Selective inhibitors of human monoamine oxidase B with neuroprotective activity.
AID232416	Ratio of inactive monoamine oxidase B between kinact and Ki	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.
AID1761635	Selectivity index, ratio of IC50 for inhibition of human MAOA to IC50 for inhibition of human MAOB	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	4-Oxoquinolines and monoamine oxidase: When tautomerism matters.
AID1465302	Inhibition of recombinant human MAO-A using kynuramine as substrate after 30 mins by fluorescence method	2017	Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22	Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID779070	Inhibition of recombinant human MAO-B expressed in insect cells using kynuramine as substrate assessed as formation of 4-hydroxyquinoline measured every 5 mins for 30 mins	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Development of a novel fluorine-18 labeled deuterated fluororasagiline ([(18)F]fluororasagiline-D2) radioligand for PET studies of monoamino oxidase B (MAO-B).
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1390036	Inhibition of recombinant human MAO-B using kynuramine as substrate after 30 mins by fluorescence assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID1525505	Inhibition of MAO-A in rat brain using [14C]-5-hydroxytryptamine creatinine disulfate as substrate preincubated for 60 mins followed by substrate addition and measured after 30 mins by liquid scintillation counting method	2019	Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20	Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1199580	Inhibition of rat brain MAO-A in nuclei-free homogenates using [14C]hydroxytryptamine substrate after 20 mins by liquid scintillation counting	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
AID1292324	Selectivity ratio of IC50 for human recombinant MAO-A to IC50 for human recombinant MAO-B	2016	Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10	Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1569980	Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate incubated for 30 mins by fluorescence based assay	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
AID1761632	Inhibition of recombinant human MAOB using kynuramine as substrate measured for 30 mins by fluorescence spectrophotometric assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	4-Oxoquinolines and monoamine oxidase: When tautomerism matters.
AID1465299	Inhibition of equine serum BuChE incubated for 15 mins by Ellman's method	2017	Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22	Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1437172	Selectivity index, ratio of IC50 for recombinant human MAO-A to IC50 for recombinant human MAO-B	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
AID1706698	Selectivity index, ratio of IC50 for recombinant human MAO-A to IC50 for recombinant human MAO-B	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Pyrimido[1,2-b]indazole derivatives: Selective inhibitors of human monoamine oxidase B with neuroprotective activity.
AID1323961	Inhibition of recombinant human MAO-B using p-tyramine as substrate assessed as decrease in H2O2 production incubated for 15 mins by fluorimetric method	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22	Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
AID1458408	Selectivity index, ratio of IC50 for human recombinant microsomal MAOA to IC50 for human recombinant microsomal MAOB	2017	Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16	Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?
AID1192631	Binding affinity to human recombinant microsomal MAO-B by ITC	2015	Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4	Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
AID1691657	Disaggregation of self-induced amyloid beta (1 to 42) (unknown origin) preformed fibrils at 25 uM measured after 24 hrs by thioflavin-T fluorescence assay relative to control	2020	European journal of medicinal chemistry, May-15, Volume: 194	Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease.
AID1754144	Cytotoxicity against C57/BL6 mouse BV-2 cells assessed as induction of cell death at 50 uM after 24 hrs by MTT assay relative to control	2021	Bioorganic & medicinal chemistry letters, 07-01, Volume: 43	Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation.
AID1872726	Inhibition of MAO-B (unknown origin) incubated for 30 mins	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Resveratrol-based compounds and neurodegeneration: Recent insight in multitarget therapy.
AID1517856	Selectivity index, ratio of IC50 for recombinant human MAO-A expressed in baculovirus infected BTI cells to IC50 for recombinant human MAO-B expressed in baculovirus infected BTI cells	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
AID1532341	Irreversible inhibition of human MAOB	2018	Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24	4-tert-Pentylphenoxyalkyl derivatives - Histamine H
AID658202	Inhibition of human recombinant MAO-B expressed in insect cells assessed as kynuramine hydrobromide oxidation after 20 mins by spectrophotometric analysis	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and evaluation of [¹⁸F]fluororasagiline, a novel positron emission tomography (PET) radioligand for monoamine oxidase B (MAO-B).
AID1639029	Inhibition of recombinant human MAOA expressed in baculovirus infected BTI insect cells using p-tyramine as substrate preincubated for 30 mins followed by substrate addition and measured over 45 mins by horseradish peroxidase-Amplex Red-coupled fluorometr	2019	Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7	Novel multi-target directed ligands based on annelated xanthine scaffold with aromatic substituents acting on adenosine receptor and monoamine oxidase B. Synthesis, in vitro and in silico studies.
AID1323965	Cytotoxicity against rat PC12 cells assessed as cell survival at 20 uM after 72 hrs by MTT assay relative to control	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22	Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1485919	Inhibition of HFIP-pretreated amyloid beta (1 to 42) (unknown origin) self-induced aggregation at 20 uM after 46 to 48 hrs by thioflavin-T fluorescence assay relative to control	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
AID1568801	Disaggregation of Cu2+ induced preformed fibrils of amyloid beta (1 to 42) (unknown origin) at 25 uM preincubated with Cu2+ for 24 hrs followed by compound addition and measured after 24 hrs by thioflavin-T based fluorescence assay relative to control	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1761237	Cytotoxicity against human SH-SY5Y cells measured after 24 hrs by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease.
AID1709260	Inhibition of recombinant human MAOA using kynuramine as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins by fluorescence assay	2021	Bioorganic & medicinal chemistry, 04-01, Volume: 35	Novel 3-benzylidene/benzylphthalide Mannich base derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
AID635344	Selectivity ratio of Ki for rat MAO-A to Ki for rat MAO-B	2011	Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24	Molecular insights into human monoamine oxidase (MAO) inhibition by 1,4-naphthoquinone: evidences for menadione (vitamin K3) acting as a competitive and reversible inhibitor of MAO.
AID1826662	Inhibition of human recombinant MAO-B at 18 nM preincubated upto 30 mins using tyramine as substrate by fluorescence assay relative to control	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades.
AID1740547	Neuroprotective activity against 6-OHDA-induced cell death in human SH-SY5Y cells assessed as increase in cell survival at 1.563 to 25 uM incubated for 24 hrs by MTT assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.
AID1465285	Inhibition of human serum BChE using butyrylthiocholine chloride as substrate incubated for 15 mins by Ellman's method	2017	Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22	Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
AID1740534	Inhibition of recombinant human MAOA expressed in baculovirus infected BTI insect cells at 100 uM using p-tyramine as substrate measured after 15 mins by Amplex red reagent based fluorescence assay relative to control	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.
AID1485914	Antioxidant activity assessed as trolox equivalent of APPH-induced radical scavenging activity at 1 to 10 uM preincubated for 15 mins followed by AAPH addition measured every minute for 120 mins by ORAC fluorescein assay	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
AID1421881	Selectivity index, ratio of IC50 for human recombinant MAOA to IC50 for human recombinant MAOB	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
AID1517863	Inhibition of equine butyrylcholinesterase using butyrylthiocholine iodide as substrate incubated for 15 mins by Ellman's method	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
AID1436077	Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate incubated for 30 mins by fluorescence assay	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
AID1751720	Selectivity index, ratio of IC50 for recombinant human MAO-A expressed in baculovirus infected BTI-TN- 5B1-4 insect cells to IC50 for recombinant human MAO-B expressed in baculovirus infected BTI-TN- 5B1-4 insect cells using kynuramine as substrate preinc	2021	Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15	Mapping Chromone-3-Phenylcarboxamide Pharmacophore:
AID1635465	Selectivity index, ratio of IC50 for human microsomal MAO-A expressed in recombinant baculovirus infected insect BTI-TN-5B1-4 cells to IC50 for human microsomal MAO-B expressed in recombinant baculovirus infected insect BTI-TN-5B1-4 cells	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.
AID1754145	Cytotoxicity against human SH-SY5Y cells assessed as induction of cell death at 50 uM after 24 hrs by MTT assay relative to control	2021	Bioorganic & medicinal chemistry letters, 07-01, Volume: 43	Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation.
AID1740538	Selectivity index, ratio of IC50 for recombinant human MAOA expressed in baculovirus infected BTI insect cells to IC50 for recombinant human MAOB expressed in baculovirus infected BTI insect cells	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.
AID1568800	Inhibition of Cu2+-induced amyloid beta (1 to 42 residues) (unknown origin) aggregation at 25 uM after 24 hrs by thioflavin-T based fluorescence assay relative to control	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1754147	Neuroprotective activity against LPS-induced oxidative stress in human SH-SY5Y cells assessed as decrease in ROS level at < 20 uM after 24 hrs by DCFH-DA dye based fluorescence assay	2021	Bioorganic & medicinal chemistry letters, 07-01, Volume: 43	Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation.
AID1556701	Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as decrease in H2O2 production using p-tyramine as substrate incubated for 20 mins by horse-radish peroxidase/amplex red-based fluorescence method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Carboxamides vs. methanimines: Crystal structures, binding interactions, photophysical studies, and biological evaluation of (indazole-5-yl)methanimines as monoamine oxidase B and acetylcholinesterase inhibitors.
AID125566	Compound was evaluated for A 450 decay towards monoamine oxidase A enzyme	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.
AID1709261	Inhibition of recombinant human MAOB using kynuramine as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins by fluorescence assay	2021	Bioorganic & medicinal chemistry, 04-01, Volume: 35	Novel 3-benzylidene/benzylphthalide Mannich base derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
AID1754142	Selectivity index, ratio of IC50 for human MAO-A to IC50 for human MAO-B	2021	Bioorganic & medicinal chemistry letters, 07-01, Volume: 43	Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation.
AID1657150	Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate measured after 30 mins by fluorescence based assay	2020	Bioorganic & medicinal chemistry, 04-15, Volume: 28, Issue:8	Design, synthesis and evaluation of phthalide alkyl tertiary amine derivatives as promising acetylcholinesterase inhibitors with high potency and selectivity against Alzheimer's disease.
AID1519690	Selectivity index, ratio of IC50 for human microsomal MAO-A expressed in baculovirus infected BTN-TN-5B1-4 cells to IC50 for human microsomal MAO-B expressed in baculovirus infected BTN-TN-5B1-4 cells using kynuramine as substrate	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies.
AID1485915	Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using p-tyramine as substrate pretreated for 15 mins followed by substrate addition after 20 mins by Amplex red reagent based fluorimetric method	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
AID1635472	Irreversible inhibition of human microsomal MAO-B expressed in recombinant baculovirus infected insect BTI-TN-5B1-4 cells assessed as decay of residual enzyme activity at 200 nM measured after first 15 mins of 60 mins	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.
AID1709264	Antioxidant activity assessed as trolox equivalent of AAPH radical scavenging activity measured every min for 90 mins by ORAC-FL assay	2021	Bioorganic & medicinal chemistry, 04-01, Volume: 35	Novel 3-benzylidene/benzylphthalide Mannich base derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
AID1528914	Inhibition of recombinant human microsomal MAOB expressed in baculovirus infected BTI insect cells using p-tyramine as substrate preincubated for 15 mins followed by substrate addition and measured over 20 mins by amplex red reagent-based horseradish pero
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1556702	Selectivity index, ratio of IC50 for human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells to IC50 for human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Carboxamides vs. methanimines: Crystal structures, binding interactions, photophysical studies, and biological evaluation of (indazole-5-yl)methanimines as monoamine oxidase B and acetylcholinesterase inhibitors.
AID1635482	Inhibition of human microsomal MAO-A expressed in recombinant baculovirus infected insect BTI-TN-5B1-4 cells assessed as reduction in H2O2 production using p-tyramine as substrate after 15 mins by fluorescence assay	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.
AID1691662	Inhibition of recombinant human MAO-B	2020	European journal of medicinal chemistry, May-15, Volume: 194	Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease.
AID1569977	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate incubated for 15 mins by Ellman's method	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
AID126540	Compound was evaluated for observed mass inactivation in human monoamine oxidase B enzyme	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1705912	Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using p-tyramine as substrate preincubated for 30 mins followed by substrate addition and measured after 1 hr by fluorimetric analysis
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1390039	Selectivity index, ratio of IC50 for recombinant human MAO-A to IC50 for recombinant human MAO-B	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID1586572	Inhibition of Sprague-Dawley rat liver MAO-A using p-tyramine as substrate preincubated for 15 mins and measured after 45 mins by resorufin-based fluorescence assay	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	(Pyrrolo-pyridin-5-yl)benzamides: BBB permeable monoamine oxidase B inhibitors with neuroprotective effect on cortical neurons.
AID1453107	Selectivity index, ratio of IC50 for recombinant human MAO-B to IC50 for recombinant human MAO-A	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID743809	Selectivity index, ratio of IC50 for human recombinant microsomal MAO-A to IC50 for human recombinant microsomal MAO-B	2013	European journal of medicinal chemistry, May, Volume: 63	Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study.
AID1458414	Time dependent inhibition of human recombinant microsomal MAOB expressed in baculovirus infected BTI-TN-5B1- 4 cells assessed as decrease in H2O2 production at 200 nM after 15 mins by amplex red-based fluorescence assay	2017	Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16	Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?
AID1761631	Inhibition of recombinant human MAOA using kynuramine as substrate measured for 30 mins by fluorescence spectrophotometric assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	4-Oxoquinolines and monoamine oxidase: When tautomerism matters.
AID1557173	Inhibition of human recombinant MAO-A using kynuramine as substrate measured after 30 mins by fluorimetric assay	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1517860	Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 30 mins by fluorescence based assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
AID1374197	Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 30 mins by fluorescence assay	2018	Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5	Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID1569978	Inhibition of equine serum BuChE using butyrylthiocholine iodide as substrate incubated for 15 mins by Ellman's method	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
AID1465287	Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 30 mins by fluorescence assay	2017	Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22	Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
AID1485916	Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using p-tyramine as substrate pretreated for 15 mins followed by substrate addition after 20 mins by Amplex red reagent based fluorimetric method	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
AID1551696	Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using p-tyramine as substrate preincubated for 60 mins followed by substrate addition and measured after 30 mins by horse-radish peroxidase-coupled amplex red reagent	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease.
AID1334743	Inhibition of human recombinant MAO-A using kynuramine as substrate measured after 30 mins by fluorescence assay	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
AID1352196	Inhibition of recombinant human MAO-B using p-tyramine as substrate preincubated for 15 mins followed by substrate addition measured over 15 mins by Amplex red reagent-based fluorimetric method	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Design, synthesis and bioevalucation of novel 2,3-dihydro-1H-inden-1-amine derivatives as potent and selective human monoamine oxidase B inhibitors based on rasagiline.
AID125561	Binding affinity towards monoamine oxidase A activity was measured using a kynuramine assay	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.
AID1557174	Inhibition of human recombinant MAO-B using kynuramine as substrate measured after 30 mins by fluorimetric assay	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1557169	Inhibition of electric eel AChE using acetylthiocholine iodide incubated for 15 mins as substrate by Ellman's method	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1192634	Inhibition of human recombinant soluble MAO-B assessed as change in melting temperature at 10 uM after 20 mins by SYPRO orange staining-based fluorescence assay	2015	Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4	Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
AID1323962	Inhibition of recombinant human MAO-A using p-tyramine as substrate assessed as decrease in H2O2 production incubated for 15 mins by fluorimetric method	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22	Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
AID1706697	Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells using p-tyramine as substrate preincubated for 15 mins followed by substrate addition and measured over 20 mins by horse-radish peroxidase/Amplex Red coupled	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Pyrimido[1,2-b]indazole derivatives: Selective inhibitors of human monoamine oxidase B with neuroprotective activity.
AID706469	Inhibition of human recombinant MAOA assessed as H2O2 production by Amplex Red reagent-based assay	2012	Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19	Multitarget-directed benzylideneindanone derivatives: anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer's disease.
AID1444066	Irreversible inhibition of human cerebral cortex MAO-B using [14C]-phenylethylamin as substrate pretreated for 60 mins followed by substrate addition after 20 mins by liquid scintillation counting method	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Discovery of highly selective and potent monoamine oxidase B inhibitors: Contribution of additional phenyl rings introduced into 2-aryl-1,3,4-oxadiazin-5(6H)-one.
AID1657140	Inhibition of HFIP-pretreated self-induced amyloid beta (1 to 42) (unknown origin) aggregation at 25 uM measured after 24 hrs by ThT fluorescence assay relative to control	2020	Bioorganic & medicinal chemistry, 04-15, Volume: 28, Issue:8	Design, synthesis and evaluation of phthalide alkyl tertiary amine derivatives as promising acetylcholinesterase inhibitors with high potency and selectivity against Alzheimer's disease.
AID1639030	Inhibition of recombinant human MAOB expressed in baculovirus infected BTI insect cells using p-tyramine as substrate preincubated for 30 mins followed by substrate addition and measured over 45 mins by horseradish peroxidase-Amplex Red-coupled fluorometr	2019	Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7	Novel multi-target directed ligands based on annelated xanthine scaffold with aromatic substituents acting on adenosine receptor and monoamine oxidase B. Synthesis, in vitro and in silico studies.
AID1427514	Selectivity index, ratio of IC50 for recombinant human MAO-A expressed in baculovirus infected BTI insect cells to IC50 for recombinant human MAO-B expressed in baculovirus infected BTI insect cells	2017	Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6	Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID1517864	Inhibition of Electric eel AChE using acetylthiocholine iodide as substrate after 15 mins by Ellman's method	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
AID1465286	Selectivity index, ratio of IC50 for human serum BChE to IC50 for human erythrocyte AChE	2017	Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22	Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
AID1199581	Inhibition of rat brain MAO-B in nuclei-free homogenates using [14C]phenylacetaldehyde substrate after 20 mins by liquid scintillation counting	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
AID1199586	Neuroprotective activity against 6-OHDA-treated rat PC12 cells assessed as survival at 10 uM after 4 hrs by MTT assay (Rvb = 100 +/- 2.31%)	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
AID1704812	Inhibition of equine serum BChE using BTCI as substrate incubated for 5 mins followed by substrate addition and measured after 5 mins by spectrophotometric based Ellman's method
AID1568799	Inhibition of self-induced amyloid beta (1 to 42) (unknown origin) aggregation at 25 uM after 24 hrs by thioflavin-T based fluorescence assay relative to control	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1334745	Inhibition of human recombinant MAO-B using kynuramine as substrate measured after 30 mins by fluorescence assay	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
AID706470	Inhibition of human recombinant MAOB assessed as H2O2 production by Amplex Red reagent-based assay	2012	Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19	Multitarget-directed benzylideneindanone derivatives: anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer's disease.
AID314095	Inhibition of MAOB	2008	Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3	Multi-target-directed ligands to combat neurodegenerative diseases.
AID1704814	Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI cells at 1 uM using p-tyramine as substrate by fluorometric assay relative to control
AID1740536	Inhibition of recombinant human MAOB expressed in baculovirus infected BTI insect cells using p-tyramine as substrate measured after 15 mins by Amplex red reagent based fluorescence assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.
AID1705913	Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells at 1 uM using p-tyramine as substrate preincubated for 30 mins followed by substrate addition and measured after 1 hr by fluorimetric analysis relative to control
AID1569983	Selectivity index, ratio of IC50 for recombinant human MAO-A expressed in baculovirus infected BTI insect cells to IC50 for recombinant human MAO-B expressed in baculovirus infected BTI insect cells	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
AID126670	Compound was evaluated for inactivation for monoamine oxidase B	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.
AID1465296	Inhibition of electric eel AChE using acetylthiocholine as substrate incubated for 15 mins by Ellman's method	2017	Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22	Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1704811	Inhibition of Electric eel AChE using ATCI as substrate incubated for 5 mins followed by substrate addition and measured after 5 mins by spectrophotometric based Ellman's method
AID1757198	Inhibition of human recombinant MAO-A by multimode plate reader assay	2021	European journal of medicinal chemistry, Apr-15, Volume: 216	Design, synthesis and evaluation of novel dimethylamino chalcone-O-alkylamines derivatives as potential multifunctional agents against Alzheimer's disease.
AID1754148	Neuroprotective activity against MPTP-induced C57BL/6J mouse model of Parkinson's disease assessed as increase in average speed at 0.2 mg/kg, ip pretreated for 7 consecutive days followed by MPTP challenge and further treated with compound until day 14 by	2021	Bioorganic & medicinal chemistry letters, 07-01, Volume: 43	Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID232325	Ratio of A450 decay monoamine oxidase B between kinact and Ki	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1374198	Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 30 mins by fluorescence assay	2018	Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5	Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID1323967	Neuroprotective activity against rotenone-induced toxicity in rat PC12 cells assessed as cell survival at 20 uM preincubated for 24 hrs followed by rotenone addition measured after 24 hrs by MTT assay relative to control	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22	Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
AID1421880	Inhibition of human recombinant MAOB expressed in baculovirus infected BTI-TN-5B1- 4 cells using p-tyramine as substrate assessed as decrease in H2O2 production by amplex red-based fluorescence assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
AID1754146	Neuroprotective activity against LPS-induced oxidative stress in C57/BL6 mouse BV-2 cells assessed as decrease in ROS level at < 20 uM after 24 hrs by DCFH-DA dye based fluorescence assay	2021	Bioorganic & medicinal chemistry letters, 07-01, Volume: 43	Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation.
AID1704810	Displacement of [3H]N-alpha-methylhistamine from recombinant human histamine H3 receptor expressed in CHO-K1 cells by microbeta scintillation analysis
AID1569982	Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate incubated for 30 mins by fluorescence based assay	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
AID1705911	Displacement of [3H]-LSD from human 5HT6 receptor expressed in HEK293 cells measured after 1 hr by microbeta plate reader method
AID1907519	Inhibition of human recombinant MAO-B using p-tyramine as substrate preincubated for 30 mins followed by substrate addition and measured after 1 hr by fluorometric analysis	2022	European journal of medicinal chemistry, Jun-05, Volume: 236	Overcoming undesirable hERG affinity by incorporating fluorine atoms: A case of MAO-B inhibitors derived from 1 H-pyrrolo-[3,2-c]quinolines.
AID1657151	Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate measured after 30 mins by fluorescence based assay	2020	Bioorganic & medicinal chemistry, 04-15, Volume: 28, Issue:8	Design, synthesis and evaluation of phthalide alkyl tertiary amine derivatives as promising acetylcholinesterase inhibitors with high potency and selectivity against Alzheimer's disease.
AID1436076	Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate incubated for 30 mins by fluorescence assay	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
AID1691659	Inhibition of self-induced Amyloid beta (1 to 42 residues) (unknown origin) aggregation at 25 uM measured after 24 hrs by thioflavin T-based fluorimetric assay relative to control	2020	European journal of medicinal chemistry, May-15, Volume: 194	Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease.
AID126544	Compound was evaluated for A 450 decay towards monoamine oxidase B enzyme	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.
AID1532335	Inhibition of human MAO-B expressed in baculovirus infected BTI insect cells using p-tyramine as substrate preincubated for 30 mins followed by substrate addition and measured after 1 hr by fluorescence-based Amplex Red MAO assay	2018	Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24	4-tert-Pentylphenoxyalkyl derivatives - Histamine H
AID1465303	Inhibition of recombinant human MAO-B using kynuramine as substrate after 30 mins by fluorescence method	2017	Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22	Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1754140	Inhibition of human MAO-B	2021	Bioorganic & medicinal chemistry letters, 07-01, Volume: 43	Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation.
AID1757199	Selectivity index, ratio of IC50 for recombinant human MAO-A to IC50 for recombinant human MAO-B	2021	European journal of medicinal chemistry, Apr-15, Volume: 216	Design, synthesis and evaluation of novel dimethylamino chalcone-O-alkylamines derivatives as potential multifunctional agents against Alzheimer's disease.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1691661	Selectivity index, ratio of IC50 for recombinant human MAO-A to IC50 for recombinant human MAO-B	2020	European journal of medicinal chemistry, May-15, Volume: 194	Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease.
AID1586576	Selectivity index, ratio of IC50 for human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect cells to IC50 for human recombinant MAO-B expressed in baculovirus infected BTI-TN-5B1-4 insect cells	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	(Pyrrolo-pyridin-5-yl)benzamides: BBB permeable monoamine oxidase B inhibitors with neuroprotective effect on cortical neurons.
AID1292320	Inhibition of human recombinant MAO-A using kynuramine as substrate after 30 mins by fluorescence spectrophotometry	2016	Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10	Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1421899	Irreversible inhibition of human recombinant microsomal MAOB expressed in baculovirus infected BTI-TN-5B1- 4 cells using p-tyramine as substrate assessed as decrease in H2O2 production at IC80 after 15 mins	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1345977	Human Monoamine oxidase B (Catecholamine turnover)	2001	British journal of pharmacology, Jan, Volume: 132, Issue:2	Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	7 (1.36)	18.7374
1990's	14 (2.71)	18.2507
2000's	145 (28.10)	29.6817
2010's	277 (53.68)	24.3611
2020's	73 (14.15)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	72 (13.46%)	5.53%
Reviews	108 (20.19%)	6.00%
Case Studies	34 (6.36%)	4.05%
Observational	5 (0.93%)	0.25%
Other	316 (59.07%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (56)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease[NCT01048229]	Phase 4	112 participants (Actual)	Interventional	2008-10-31	Terminated(stopped due to recruitment)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Rasagiline in Subjects With Progressive Supranuclear Palsy (Phase III)[NCT01187888]	Phase 3	44 participants (Actual)	Interventional	2010-01-31	Terminated(stopped due to IMP used off label by phys. in pat. with PSP. Thus no more eligible patients were available for the study(pre-treatm.with Rasagiline=exclusion criterion)
Safety and Efficacy of Rasagiline in Restless Legs Syndrome[NCT01192503]	Phase 2/Phase 3	52 participants (Actual)	Interventional	2010-09-30	Terminated(stopped due to Slow enrollment)
Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.[NCT02278588]		45 participants (Actual)	Observational	2014-11-30	Completed
Spontaneous and Evoked Pain in Parkinson's Disease With Motor Fluctuations: an Observational, Prospective, Clinical and Neurophysiological Study in Patients Under L-dopa Add on Therapies.[NCT03648671]		48 participants (Anticipated)	Observational	2018-03-28	Recruiting
Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease[NCT05611372]	Phase 2/Phase 3	732 participants (Anticipated)	Interventional	2023-01-01	Not yet recruiting
A Multicenter, Randomized, Double-blind Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease (PD)[NCT01178047]	Phase 4	1 participants (Actual)	Interventional	2011-09-30	Terminated(stopped due to payments stopped by grant provider)
[NCT01382342]	Phase 4	50 participants (Actual)	Interventional	2011-06-30	Completed
A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)[NCT00977665]	Phase 2	174 participants (Actual)	Interventional	2009-12-31	Completed
Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment[NCT02068625]	Phase 4	23 participants (Actual)	Interventional	2010-09-30	Terminated(stopped due to Persisting recruitment difficulties)
Investigation of the Occurrence of Serotonin Toxicity in Parkinson's Disease (PD) Patients Treated Concomitantly With Rasagiline and Antidepressants, Using Retrospective Chart Review[NCT00955604]		1,500 participants (Anticipated)	Observational	2009-07-31	Completed
A Randomised Placebo-controlled Trial of Rasagiline in Parkinson Disease Patients With Symptoms of Apathy[NCT00755027]	Phase 4	40 participants (Actual)	Interventional	2008-09-30	Completed
A Sensorimotor Contingency-based Musical Walking Program for People Living With Parkinson's Disease[NCT02207387]		60 participants (Anticipated)	Interventional	2013-10-31	Recruiting
Reversibility of Olfactory Loss in Patients With Idiopathic Parkinson's Disease Following Treatment With Rasagiline[NCT00902941]	Phase 4	34 participants (Actual)	Interventional	2009-05-31	Completed
Efficacy, Safety and Tolerability Study of 1 mg Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole) - An AMG Trial With a Market Authorized Substance[NCT01879241]	Phase 2	252 participants (Actual)	Interventional	2013-06-30	Completed
A Prospective Randomized Placebo-Controlled Double-Blind Study Assessing Change in Olfactory Function After Initiation of Rasagiline in Idiopathic Parkinson's Disease[NCT01007630]	Phase 4	36 participants (Anticipated)	Interventional	2009-11-30	Active, not recruiting
The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Over 3 Months[NCT00696215]	Phase 4	40 participants (Anticipated)	Interventional	2007-06-30	Recruiting
A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)[NCT01215227]	Phase 3	839 participants (Actual)	Interventional	2010-11-18	Terminated
Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease: A Bi-Center, Placebo-Controlled Study (The REST Fatigue Trial)[NCT01168596]	Phase 4	30 participants (Actual)	Interventional	2009-12-31	Completed
A Phase 3, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose-Range-Finding Efficacy and Safety Study of Preladenant in Subjects With Early Parkinson's Disease[NCT01155479]	Phase 3	1,022 participants (Actual)	Interventional	2010-07-06	Terminated(stopped due to Termininated for business reasons)
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study[NCT00936676]		684 participants (Actual)	Observational	2009-07-31	Completed
Effects of Azilect (Rasagiline) on Processing of Emotions, Mood and Executive Function in Parkinson's Disease[NCT01385735]	Phase 4	70 participants (Anticipated)	Interventional	2011-10-31	Not yet recruiting
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease[NCT01968460]	Phase 2/Phase 3	149 participants (Actual)	Interventional	2013-12-31	Completed
Evaluation for the Efficacy,Tolerability,and Safety of Rasagiline in Levodopa-treated PD Patients With Motor Fluctuations: A Multicenter, Double Blind, Randomized, Placebo-Controlled Group Study (China)[NCT01736891]	Phase 3	268 participants (Actual)	Interventional	2011-11-30	Completed
A Randomised, Double-blind, Placebo-controlled Study to Evaluate if Rasagiline Can Improve Depressive Symptoms and Cognitive Function in Non-demented, Idiopathic Parkinson's Disease Patients: ACCORDO Study[NCT01055379]	Phase 4	121 participants (Actual)	Interventional	2010-03-31	Completed
An Open-Label, Multi-Center, Single Arm Study to Evaluate the Effects of Azilect® on Sleep Disturbances in Parkinson's Disease Subjects[NCT01032486]		120 participants (Actual)	Observational	2009-12-31	Completed
A Multi Center, Double Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects[NCT00256204]	Phase 3	1,174 participants (Actual)	Interventional	2005-11-30	Completed
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses (0.5, 1.0, and 2.0 mg) of Rasagiline Administered to Healthy Japanese and Caucasian Subjects[NCT01879748]	Phase 1	64 participants (Actual)	Interventional	2013-06-30	Completed
A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Clinical Trial For The Efficacy, Tolerability And Safety Of Two Doses Of Rasagiline Mesylate In Early Parkinson's Disease (PD) Patients Not Treated With Levodopa[NCT00203060]	Phase 3	404 participants (Actual)	Interventional	1997-07-31	Completed
A Multicenter, Open-Label, Phase III Study for the Safety, Tolerability and Clinical Effect of Rasagiline Mesylate in Patients With Parkinson's Disease[NCT00203138]	Phase 3	306 participants (Actual)	Interventional	2004-06-30	Completed
A Bi-national, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Chronic Levodopa/Carbidopa Therapy.[NCT00203177]	Phase 3	254 participants (Actual)	Interventional	2001-10-31	Completed
A Phase 3, Twelve-week Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to Its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER.[NCT03329508]	Phase 3	544 participants (Actual)	Interventional	2018-01-19	Completed
A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3;Protocol No. P04938)[NCT01155466]	Phase 3	778 participants (Actual)	Interventional	2010-07-14	Completed
Azilect® In Wearing-Off (AIWO) Non-interventional Study on Efficacy and Tolerability of Rasagiline (1mg/d) add-on in Ambulatory Parkinson's Disease Patients With Wearing-off Symptoms Diagnosed by Wearing-off Questionnaire (WOQ-32)[NCT02384512]		261 participants (Actual)	Observational	2014-01-31	Completed
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)[NCT01232738]	Phase 2	36 participants (Actual)	Interventional	2011-12-31	Completed
A Multicenter, US and Canada, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study, for the Efficacy, Tolerability and Safety of Rasagiline Mesylate in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations[NCT00203034]	Phase 3	472 participants (Actual)	Interventional	2000-05-31	Completed
Image Parkinson's Disease Progression Study[NCT02789020]	Phase 2	96 participants (Actual)	Interventional	2016-12-31	Completed
Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of [Azilect®] Rasagiline in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China[NCT01479530]	Phase 3	321 participants (Actual)	Interventional	2011-12-31	Completed
A 1-Year, Double-Blind, Randomized, Placebo-Controlled, Study of Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Dementia of the Alzheimer's Type[NCT00104273]	Phase 2	376 participants (Actual)	Interventional	2004-08-31	Completed
Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia[NCT00492336]	Phase 4	84 participants (Actual)	Interventional	2007-01-31	Completed
Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of [Azilect®] Rasagiline in Levodopa-treated Parkinson's Patients With Motor Fluctuations in Korea[NCT01268891]	Phase 3	132 participants (Actual)	Interventional	2011-01-31	Completed
Sub-study to Evaluate the Effect of An Oral Dose of Tyramine in Subjects Completing 26 Weeks of Participation in PRESTO (TVP-1012/133)[NCT00203125]	Phase 3	55 participants (Actual)	Interventional	2000-10-31	Completed
A Bi-national, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Chronic Levodopa/Carbidopa Therapy[NCT00203164]	Phase 3	254 participants (Actual)	Interventional	2002-05-31	Completed
Open-label, Multicenter, Effectiveness and Safety Study of Once Daily AZILECT® as Mono- or Adjunct Therapy in Patients With Idiopathic Parkinson's Disease (PD)[NCT00399477]	Phase 4	200 participants (Actual)	Interventional	2006-10-31	Completed
"AZILECT Tablets Special Drug Use-Results Survey Survey on Long-term Safety"[NCT03727139]		1,021 participants (Actual)	Observational	2018-11-01	Completed
Effect of Rasagiline on BIA 9-1067 Pharmacokinetics in Healthy Subjects[NCT01532141]	Phase 1	25 participants (Actual)	Interventional	2009-11-30	Completed
A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy[NCT01497652]	Phase 4	34 participants (Actual)	Interventional	2012-01-31	Completed
A Double-blind, Placebo Controlled, Randomized, Multicenter Study to Assess the Safety and Clinical Benefit of Rasagiline as an Add on Therapy to Stable Dose of Dopamine Agonists in the Treatment of Early Parkinson's Disease[NCT01049984]	Phase 4	328 participants (Actual)	Interventional	2009-12-31	Completed
A Single Centre, Open-label, Multiple-dose Interventional Study Investigating the Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women[NCT01652313]	Phase 1	12 participants (Actual)	Interventional	2012-05-31	Completed
Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study.[NCT01765257]	Phase 4	50 participants (Anticipated)	Interventional	2013-06-30	Not yet recruiting
Effects of Rasagiline on Sleep Disturbances in PD: A Single Center, Randomized, Double-blind, Placebo run-in, Polysomnographic Clinical Phase IV Trial[NCT01442610]	Phase 4	30 participants (Actual)	Interventional	2011-10-31	Completed
Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China[NCT01556165]	Phase 3	130 participants (Actual)	Interventional	2012-04-30	Completed
A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease[NCT01723228]	Phase 4	170 participants (Actual)	Interventional	2012-11-30	Completed
Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis[NCT01786603]	Phase 2	80 participants (Actual)	Interventional	2013-11-21	Completed
Effect of BIA 9-1067 on Rasagiline Pharmacokinetics in Healthy Subjects[NCT01532128]	Phase 1	24 participants (Actual)	Interventional	2009-11-30	Completed
A 24-week, Three-site, Randomized, Double Blind, Placebo Controlled, Parallel Group, Proof-of-concept Study to Evaluate Rasagiline in the Regional Brain Metabolism on FDG PET in Patients With Mild to Moderate Alzheimer's Disease[NCT02359552]	Phase 2	50 participants (Actual)	Interventional	2015-05-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline to Week 12 in Total UMSARS Score for Symptomatic Effect

This outcome represents the sum of 2 UMSARS sub-scales: Part I: Historical Review that includes 12 items and Part II: Motor Examination that includes 14 items. All items range from 0 to 4. Each subscale score is the sum of its items and the total UMSARS score is the sum of all 26 items. Hence the total UMSARS score can range from 0 to 104, with 0 meaning no impairment and 104 indicating severe impairment. Negative change from baseline scores indicate improvement. (NCT00977665)
Timeframe: Day 0 (baseline), Week 12

Intervention	units on a scale (Mean)
Rasagiline Mesylate	1.875
Placebo	1.574

Change From Baseline to Week 24 in Total Unified Multiple System Atrophy Rating Scale (UMSARS) Score

"The UMSARS is composed of 2 sub-scales: Part I: Historical Review that includes 12 items and Part II: Motor Examination that includes 14 items. All items range from 0 to 4. Each subscale score is the sum of its items and the total UMSARS score is the sum of all 26 items. Hence the total UMSARS score can range from 0 to 104, with 0 meaning no impairment and 104 indicating severe impairment. Negative change from baseline scores indicate improvement.~In the case that 6 items or more (out of 26) were missing at a certain visit, the UMSARS score for that visit was assigned a missing value." (NCT00977665)
Timeframe: Day 0 (baseline), Week 24

Intervention	units on a scale (Least Squares Mean)
Rasagiline Mesylate	3.8
Placebo	3.0

Change From Baseline to Week 48 or Termination in the Beck Depression Inventory Scale (BDI-II)

The Beck Depression Inventory (BDI-II), is a 21-question multiple-choice self-report inventory, one of the most widely used instruments for measuring the severity of depression. Participants are asked to pick the answer for each question that best describes the way they have been feeling in the past two weeks, including the day participants complete the questionnaire. Each question is rated on a scale of 0-3, with 0 meaning the participant does not feel the emotion described in the question, and 3 meaning the participant has extremely strong feelings. Total scale is 0 (no evidence of depression) to 63 (extreme depression). Negative change from baseline scores indicate improvement in level of depression. (NCT00977665)
Timeframe: Day 0 (baseline), Week 48 or termination visit

Intervention	units on a scale (Least Squares Mean)
Rasagiline Mesylate	0.4894
Placebo	0.7145

Change From Baseline to Week 48 or Termination in the Montreal Cognitive Assessment Scale (MoCA) Scale

MoCA is a cognitive screening test which helps health professionals identify mild cognitive impairment. The total scale is 0 (significant cognitive impairment) to 30 (no impairment detected). Scores >=26 are considered normal. Positive change from baseline scores indicate improvement in cognition. (NCT00977665)
Timeframe: Day 0 (baseline), Week 48 or termination visit

Intervention	units on a scale (Least Squares Mean)
Rasagiline Mesylate	-1.1572
Placebo	-0.5786

Change From Baseline to Week 48/Termination Visit in the Multiple System Atrophy (MSA) Health-related Quality of Life (QoL) Scale

"The Multiple System Atrophy Quality of Life questionnaire (MSA-QoL) is a self-reported questionnaire focusing on MSA-specific symptoms and has a scale ranging from 0 - 160, with 0= 'no problem' and 160= extreme problem." (NCT00977665)
Timeframe: Day 0 (baseline), Week 48

Intervention	units on a scale (Least Squares Mean)
Rasagiline Mesylate	4.6
Placebo	9.3

Change From Baseline to Week 48/Termination Visit in the Total Unified Multiple System Atrophy Rating Scale (UMSARS Part I and II)

"This outcome represents the sum of 2 UMSARS sub-scales: Part I: Historical Review that includes 12 items and Part II: Motor Examination that includes 14 items. All items range from 0 to 4. Each subscale score is the sum of its items and the total UMSARS score is the sum of all 26 items. Hence the total UMSARS score can range from 0 to 104, with 0 meaning no impairment and 104 indicating severe impairment. Negative change from baseline scores indicate improvement.~In the case that 6 items or more (out of 26) were missing at a certain visit, the UMSARS score for that visit was assigned a missing value." (NCT00977665)
Timeframe: Day 0 (baseline), Week 48

Intervention	units on a scale (Least Squares Mean)
Rasagiline Mesylate	7.2
Placebo	7.8

Clinical Global Impression Improvement (CGI-I) at Week 48/Termination Visit

"Outcome measures the investigator's clinical impression of the participants' improvement at Week 48 as compared to Week 12. CGI scale range from 1-7, with 1=very much improved, 4= no change, and 7=very much worse.~In order to maintain the overall (hypotheses about primary and key secondary endpoints) type I error at the 0.05 level an hierarchy will be employed as follows: If the primary endpoint will be found to be significant at a significance level of 0.05 then the first key secondary endpoint will be tested, if this endpoint will be found to be significant in a significance level of 0.05 then the second key secondary endpoint will be tested and so on. The 'key' secondary endpoints are outcomes 2-6." (NCT00977665)
Timeframe: Week 48

Intervention	units on a scale (Least Squares Mean)
Rasagiline Mesylate	4.9
Placebo	4.8

Estimates for Time to Change in Anti-Parkinsonian or Anti-Orthostatis Hypotension Medications

"Change in anti-parkinsonian or anti-orthostatic hypotension medication is defined by at least one of the following events:~An addition of a new anti-parkinsonian or anti-orthostatic hypotension medication during study.~Dose modification of anti-parkinsonian or anti-orthostatic hypotension concomitant medications reflecting disease progression.~The event of interest, determined on a by patient basis, therefore, is the earliest event of the two events defined above. Otherwise, patient is right censored according to his/her study termination date.~Since less than 25% of participants had an event, median estimatation for time to change in medications is not possible." (NCT00977665)
Timeframe: Day 0 (baseline) to Week 48 or termination visit

Intervention	days (Median)
Rasagiline Mesylate	246
Placebo	294

Mean Score of the Composite Autonomic Symptom Scale Select (COMPASS_Select Change) at Week 48/Termination Visit

COMPASS_Select change is comprised of 5 of the 11 domains in the COMPASS scale: Orthostatic Intolerance, Bladder Disorder, Sweating, Vasomotor, and Sleep Disorder COMPASS_Select change has a range of -150 to 150, with -150 indicating symptoms are much better and 150 indicating symptoms are much worse. (NCT00977665)
Timeframe: 48 weeks

Intervention	units on a scale (Least Squares Mean)
Rasagiline Mesylate	34.1
Placebo	42.7

Percentage of Participants Who Achieved a Score of >=3 on the Unified Multiple System Atrophy Rating Scale (UMSARS) Question #7 Regarding Ambulation

UMSARS' Question #7 concerns the participant's ability to walk, rated on a scale of 0=normal to 4=cannot walk at all even with assistance. This endpoint counts participants rated a 3 or worse. Rating 3 = Severely impaired; assistance and/or walking aid needed occasionally. (NCT00977665)
Timeframe: up to week 48

Intervention	percentage of participants (Number)
Rasagiline Mesylate	46.4
Placebo	52.2

Rate of Progression in Total Unified Multiple System Atrophy Rating Scale (UMSARS) Score From Baseline to Weeks 12-48

"The UMSARS is composed of 2 sub-scales: Part I: Historical Review that includes 12 items and Part II: Motor Examination that includes 14 items. All items range from 0 to 4. Each subscale score is the sum of its items and the total UMSARS score is the sum of all 26 items. Hence the total UMSARS score can range from 0 to 104, with 0 meaning no impairment and 104 indicating severe impairment.~The rate of progression of atrophy is represented by the slope of change from baseline scores for visits between Weeks 12 and 48." (NCT00977665)
Timeframe: Day 0 (baseline), Weeks 12-48

Intervention	units on a scale/week (Mean)
Rasagiline Mesylate	0.1496
Placebo	0.1788

Total Number of Falls During the Study

Participants recorded each time they fell during the study in a diary. (NCT00977665)
Timeframe: Day 1 up to week 48

Intervention	falls (Median)
Rasagiline Mesylate	4.00
Placebo	5.00

Change From Baseline to Week 48 or Termination in UMSARS Subscores for Parts I, II and IV

UMSARS Part I is an historical review and scores symptoms of neurological and autonomic dysfunction with 12 items rated on a scale of 0 (normal) to 4 (extreme dysfunction). The full scale for Part 1 is therefore 0 (normal) to 48 (extreme dysfunction). Part II is a motor examination and has 14 items also rated on a scale of 0 to 4 for a full scale of 0 (normal) to 56 (extreme dysfunction). Part IV is a global disability scale with rates the extent of disease from 1 (normal) to 5 (severe disease). (NCT00977665)
Timeframe: Day 0 (baseline), Week 48 or termination visit

Intervention	units on a scale (Least Squares Mean)
	UMSARS Part I	UMSARS Part II	UMSARS Part IV
Placebo	4.3785	3.5068	0.6763
Rasagiline Mesylate	3.8233	3.6478	0.7100

Percentage of Participants Who Achieved a Score of >=3 on the Unified Multiple System Atrophy Rating Scale (UMSARS) Question #1 (Speech Impairment), Question #2 (Swallowing Impairment) and Question #8 (Falling)

"UMSARS' questions are rated on a scale of 0=normal to 4=extreme impairment.~This endpoint reports the percentage of participants rated a 3 or worse. Rating 3 = Severely impaired speech (Question #1), swallowing (Question #2) or falling more frequently than once per week (Question #8)." (NCT00977665)
Timeframe: up to week 48

Intervention	percentage of participants (Number)
	Q1. Speech Impairment	Q2. Swallowing Impairment	Q8. Falling
Placebo	30.0	6.7	15.6
Rasagiline Mesylate	35.7	3.6	19.0

Percentage Change From Baseline in Total Epworth Sleepiness Scale (ESS) Score at Week 40

The ESS is a self-administered questionnaire providing a measure of a person's general level of daytime sleepiness, or their average sleep propensity in daily life. The scale consists of 8 situations in which the participant rates their tendency to become sleepy on a scale of 0=no chance of dozing to 3=high chance of dozing. The overall score is the sum of the scores for the 8 situations for a minimum of 0 and a maximum of 24 with a higher score indicating greater sleepiness. (NCT01215227)
Timeframe: Baseline and Week 40

Intervention	Percentage change (Mean)
Preladenant 2 mg	15.5
Preladenant 5 mg	24.0
Preladenant 5 mg (on Placebo in Parent Study)	22.5
Preladenant 10 mg	13.2
Rasagiline 1 mg	8.3
Rasagiline 1 mg (on Placebo in Parent Study)	16.3

Percentage of Participants With Alanine Aminotransferase (ALT) ≥3 Times Upper Limit of Normal and ≥10% Increase From Baseline

The number of participants with ALT ≥3 times the upper limit of normal and a ≥10% increase was reported. Laboratory safety blood work was collected from participants at Week 4, Week 6, and Week 8 visits. (NCT01215227)
Timeframe: Up to 42 weeks

Intervention	Percentage of participants (Number)
Preladenant 2 mg	1.4
Preladenant 5 mg	0.5
Preladenant 5 mg (on Placebo in Parent Study)	0.0
Preladenant 10 mg	1.0
Rasagiline 1 mg	0.0
Rasagiline 1 mg (on Placebo in Parent Study)	1.9

Percentage of Participants With Aspartate Aminotransferase (AST) ≥3 Times Upper Limit of Normal and ≥10% Increase From Baseline

The number of participants with AST ≥3 times the upper limit of normal and a ≥10% increase was reported. Laboratory safety blood work was collected from participants at Week 4, Week 6, and Week 8 visits. (NCT01215227)
Timeframe: Up to 42 weeks

Intervention	Percentage of participants (Number)
Preladenant 2 mg	1.4
Preladenant 5 mg	0.5
Preladenant 5 mg (on Placebo in Parent Study)	0.0
Preladenant 10 mg	2.1
Rasagiline 1 mg	1.1
Rasagiline 1 mg (on Placebo in Parent Study)	2.8

Percentage of Participants With Diastolic Blood Pressure ≥105 mmHg

The percentage of participants with Diastolic Blood Pressure ≥105 mmHg was reported. On Day 1 and Early Termination, blood pressure was measured as follows: Participant lay supine for 5 minutes, then had blood pressure taken; then stood for 3 minutes and had blood pressure taken; then rested for 10 minutes, at which time the process was repeated twice (ie, three rounds total). For all other blood pressure measurements, the procedure needed only to be done once (ie, one round). (NCT01215227)
Timeframe: Up to 42 weeks

Intervention	Percentage of participants (Number)
Preladenant 2 mg	5.0
Preladenant 5 mg	4.2
Preladenant 5 mg (on Placebo in Parent Study)	5.7
Preladenant 10 mg	5.2
Rasagiline 1 mg	7.5
Rasagiline 1 mg (on Placebo in Parent Study)	8.3

Percentage of Participants With Suicidality

The number of participants with suicidality using the Columbia - Suicide Severity Rating Scale (C-SSRS) was reported. The C-SSR was used in this study only for the purpose of safety monitoring by measuring the incidence of different types of suicidality categories during treatment. The assessment was done by the nature of the responses, not by a numbered scale. Participants who reported at least one occurrence of suicidal behavior or suicidal ideation were counted as having experienced suicidality. Suicidal behavior included suicide attempt, aborted attempt, interrupted attempt, or preparatory behavior. Suicidal ideation included a wish to die or active suicidal thought with or without method, intent or plan. (NCT01215227)
Timeframe: Up to 42 weeks

Intervention	Percentage of participants (Number)
Preladenant 2 mg	4.1
Preladenant 5 mg	5.6
Preladenant 5 mg (on Placebo in Parent Study)	0.0
Preladenant 10 mg	4.2
Rasagiline 1 mg	2.2
Rasagiline 1 mg (on Placebo in Parent Study)	2.8

Percentage of Participants With Systolic Blood Pressure ≥180 mmHg

The percentage of participants with Systolic Blood Pressure ≥180 mm Hg was reported. On Day 1 and Early Termination, blood pressure was measured as follows: Participant lay supine for 5 minutes, then had blood pressure taken; then stood for 3 minutes and had blood pressure taken; then rested for 10 minutes, at which time the process was repeated twice (ie, three rounds total). For all other blood pressure measurements, the procedure needed only to be done once (ie, one round). (NCT01215227)
Timeframe: Up to 42 weeks

Intervention	Percentage of participants (Number)
Preladenant 2 mg	1.4
Preladenant 5 mg	0.0
Preladenant 5 mg (on Placebo in Parent Study)	0.9
Preladenant 10 mg	1.0
Rasagiline 1 mg	0.0
Rasagiline 1 mg (on Placebo in Parent Study)	0.9

Becks Depression Inventory (BDI-II)

The Becks Depression Inventory (BDI-II) is a 21-question inventory measuring the severity of depression. Each subject is instructed to choose an answer on a scale value of 0 to 3 with the total score from 0 to 63. Higher total scores indicate more severe depressive symptoms. (NCT01168596)
Timeframe: Change from baseline to week 12

Intervention	units on a scale (Mean)
Rasagiline	3.69
Sugar Pill	2.31

Fatigue Severity Scale (FSS)

The Fatigue Severity Score consists of a nine-item questionnaire to identify common features of fatigue. Patients are instructed to choose a number from 1 to 7 that indicates their degree of agreement with each statement, where 1 = strongly disagree and 7 = strongly agree. Scores can range from a minimum of 9 to a maximum of 63. The higher the score, the more fatigue the subject. (NCT01168596)
Timeframe: Change from baseline to week 12

Intervention	units on a scale (Mean)
Rasagiline	12.38
Sugar Pill	2.25

Finger Tapping

The patient is asked to use the index finger on the side most affected by Parkinson's disease to tap for sixty seconds with the number of taps at 30 seconds and 60 seconds recorded. (NCT01168596)
Timeframe: Change from baseline to week 12

Intervention	finger taps per sixty seconds (Mean)
Rasagiline	.46
Sugar Pill	-0.23

Hand-grip Strength

The patients use the hand on the side most affected by Parkinson's disease to grip the dynamometer with as much strength as they can for 3 consecutive tries. The highest score will be their maximal voluntary contraction (MVC). The subject then rests for 60 seconds. The subject is asked to try to maintain 70% of their MVC and the duration the subject is able to maintain above 50% of their MVC is recorded. Immediately after the maintenance test, the subject performs three more MVCs and each one is recorded. These results are the duration the subject is able to maintain above 50% of their MVC. (NCT01168596)
Timeframe: Change from baseline to week 12

Intervention	seconds (Mean)
Rasagiline	-9.08
Sugar Pill	-8.36

Marin Apathy Inventory (Apathy Evaluation Scale)

The Marin Apathy Inventory (Apathy Evaluation Scale) is a 14-item inventory measuring apathy of the subject over the past 2 to 4 weeks. Subjects are instructed to choose an answer from 0 to 3: 0=not at all, 1 = slightly, 2 = some, 3 = a lot, to questions related to apathy. The range would be 0 to 42, the higher the score the worse the apathy. (NCT01168596)
Timeframe: Change from baseline to week 12

Intervention	units on a scale (Mean)
Rasagiline	.23
Sugar Pill	.46

Modified Fatigue Impact Scale (MFIS)

The MFIS rates how much of a problem fatigue has caused the subjects during the past month, including the day of testing. It consists of 21 questions of fatigue on quality of life. Each subject is asked to circle the appropriate response for each item: 0=never, 1=rarely, 2=sometimes, 3=often, 4=always, 5=almost always. The minimum score is 0 and the maximum is 105. The higher the score, the more fatigue the subject. (NCT01168596)
Timeframe: Change from baseline to week 12

Intervention	units on a scale (Mean)
Rasagiline	12.92
Sugar Pill	12.69

Multidimensional Fatigue Inventory (MFIS)

The Multidimensional Fatigue Inventory (MFIS) is a 20-item self-report instrument designed to measure fatigue. It covers the following dimensions: general fatigue, physical fatigue, mental fatigue, reduced motivation and reduced activity. Subjects are instructed to choose a number from 1 to 5 that indicates their degree of agreement with each statement where 1 indicates that it is true and 5 that it is not true. There are positive and negative statements in the questionnaire. The range is 1 to 100, the higher the number the higher the fatigue. (NCT01168596)
Timeframe: Change from baseline to week 12

Intervention	units on a scale (Mean)
Rasagiline	2.62
Sugar Pill	6.83

Paced Auditory Serial Addition Test (PASAT)

The Paced Auditory Serial Addition Test (PASAT) is a neuropsychological test used to assess capacity and rate of information processing and sustained and divided attention. Where subjects are given a number (every 3 seconds for the first series and 2 seconds for the second series) and are asked to add the number they just heard with the number they heard before. This is a challenging task that involves working memory, attention, and arithmetic capabilities. (NCT01168596)
Timeframe: Change from baseline to week 12

Intervention	units on a scale (Mean)
Rasagiline	-11.31
Sugar Pill	-10.31

Parkinson's Disease Sleep Scale (PDSS)

The Parkinson's disease sleep scale (PDSS) is a 15-item visual analogue scale that assesses the profile of nocturnal disturbances in Parkinson's disease patients. The severity of symptoms of sleep over the past week is marked with a cross along a 10 cm line (labeled worst to best state). Responses are quantified by measuring the distance along each line to the intersection with the cross in centimetres, to the nearest 0.1 cm. The scores for each item range from 0 (symptom severe and always experienced) to 10 (symptom-free). The maximum score for PDSS is 150. (NCT01168596)
Timeframe: Change from baseline to week 12

Intervention	units on a scale (Mean)
Rasagiline	-13.46
Sugar Pill	.64

PD Quality of Life Scale (PDQ39)

PD Quality of Life Scale (PDQ39) is a 39-item questionnaire, which measures eight dimensions of health (mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communication and bodily discomfort) over the past 30 days. Dimension scores are coded on a scale of 0 (never) to 5 (always). The higher the score, the worse the quality of life affected by PD. The range for this test is 0 to 195. All eight dimensions are added for a total score. (NCT01168596)
Timeframe: Change from baseline to week 12

Intervention	units on a scale (Mean)
Rasagiline	7.54
Sugar Pill	5.67

State-Trait Anxiety Inventory (STAI)

The State-Trait Anxiety Inventory (STAI) is 40-item psychological inventory based on a 4-point Likert scale. Higher scores are positively correlated with higher levels of anxiety. The range for this test is 0 to 160. (NCT01168596)
Timeframe: Change from baseline to week 12

Intervention	units on a scale (Mean)
Rasagiline	3.62
Sugar Pill	6.08

Unified Parkinson's Disease Rating Scale - Motor (UPDRS Part III)

Unified Parkinson's Disease Rating Scale - Motor (UPDRS Part III)is a 14-question inventory measuring the motor functions of patients with Parkinson's Disease. Each subject is rated on a scale of 0 to 4 with the total score from 0 to 56. Higher total scores indicate more impairment of motor function. (NCT01168596)
Timeframe: Change from baseline to week 12

Intervention	units on a scale (Mean)
Rasagiline	7.5
Sugar Pill	-0.83

Visual Analog Scale - Subset: Afraid

The Visual Analog Scale is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured. The severity of attitude at the time of testing is marked with a cross along a 10 cm line (labeled neutral to afraid, confused, sad, angry, energetic, tired, happy or tense). Responses are quantified by measuring the distance along each line to the intersection with the cross in centimetres, to the nearest 0.1 cm. The scores for each item range from 0 (symptoms-free) to 10 (symptom severe). (NCT01168596)
Timeframe: Change from baseline to week 12

Intervention	units on a scale (Mean)
Rasagiline	-.77
Sugar Pill	-.83

Visual Analog Scale - Subset: Angry

Intervention	units on a scale (Mean)
Rasagiline	.19
Sugar Pill	.33

Visual Analog Scale - Subset: Confused

Intervention	units on a scale (Mean)
Rasagiline	-.35
Sugar Pill	-.21

Visual Analog Scale - Subset: Energetic

Intervention	units on a scale (Mean)
Rasagiline	-1.19
Sugar Pill	-2.12

Visual Analog Scale - Subset: Happy

Intervention	units on a scale (Mean)
Rasagiline	.04
Sugar Pill	-0.33

Visual Analog Scale - Subset: Sad

Intervention	units on a scale (Mean)
Rasagiline	-.19
Sugar Pill	-.5

Visual Analog Scale - Subset: Tense

Intervention	units on a scale (Mean)
Rasagiline	.25
Sugar Pill	.83

Visual Analog Scale - Subset: Tired

Intervention	units on a scale (Mean)
Rasagiline	.04
Sugar Pill	.75

Change From Baseline in the Sum of Unified Parkinson's Disease Rating Scale Parts 2 and 3 Scores (UPDRS2+3)

The UPDRS is a clinician based rating scale used to measure motor impairments and disability. The UPDRS assesses six features of PD impairment. These are evaluated using a combination of data collected by interview and examination of the participant. The UPDRS Part 2 is the Activities of Daily Living (ADL) score and can range from 0-52 as determined by the physician. The UPDRS Part 3 is the Motor Examination (Total Motor Score [TMS]) and is defined as the total score, ranging from 0-108 as determined by the physician, of the tests given in the motor examination section. The combined scores of Parts 2 and 3 can range from 0-160 with the higher score indicating the worse condition. Change from baseline was analyzed using a constrained longitudinal analysis (cLDA) model with treatment, time, strata and treatment-by-time interaction as fixed effects and participant as a random effect. (NCT01155479)
Timeframe: Baseline and Week 26

Intervention	Score on a Scale (Mean)
Preladenant 2 mg (Part 1)	0.3
Preladenant 5 mg (Part 1)	-1.0
Preladenant 10 mg (Part 1)	-1.8
Placebo (Part 1)	-2.2
Rasagiline (Part 1)	-1.9

Change From Baseline in the UPDRS Part 2 Score (Activities of Daily Living [ADL])

Intervention	Score on a Scale (Mean)
Preladenant 2 mg (Part 1)	0.30
Preladenant 5 mg (Part 1)	0.10
Preladenant 10 mg (Part 1)	-0.20
Placebo (Part 1)	-0.40
Rasagiline (Part 1)	-0.20

Number of Participants Who Discontinued Study Due to an AE in Part 1

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. (NCT01155479)
Timeframe: Day 1 to Week 26

Intervention	Participants (Number)
Preladenant 2 mg (Part 1)	13
Preladenant 5 mg (Part 1)	8
Preladenant 10 mg (Part 1)	20
Placebo (Part 1)	8
Rasagiline (Part 1)	6

Number of Participants Who Discontinued Study Due to an AE in Part 2

Intervention	Participants (Number)
Preladenant 2 mg (Part 2)	7
Preladenant 5 mg (Part 2)	5
Preladenant 10 mg (Part 2)	8
Placebo (Part 2)	3
Rasagiline (Part 2)	4

Number of Participants With Adverse Events (AEs) in Part 1

An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. (NCT01155479)
Timeframe: Day 1 to Week 26

Intervention	Participants (Number)
Preladenant 2 mg (Part 1)	108
Preladenant 5 mg (Part 1)	110
Preladenant 10 mg (Part 1)	121
Placebo (Part 1)	102
Rasagiline (Part 1)	105

Number of Participants With Adverse Events (AEs) in Part 2

Intervention	Participants (Number)
Preladenant 2 mg (Part 2)	116
Preladenant 5 mg (Part 2)	120
Preladenant 10 mg (Part 2)	113
Placebo (Part 2)	120
Rasagiline (Part 2)	119

Percentage of Responders (Participants With a ≥20% Improvement in UPDRS2+3)

UPDRS is a clinician based rating scale used to measure motor impairments and disability; it assesses 6 features of PD impairment. These are evaluated using a combination of data collected by interview and examination of the participant. UPDRS Part 2 is Activities of Daily Living score and ranges from 0-52. UPDRS Part 3 is Motor Examination and ranges from 0-108. The combined scores of Parts 2 and 3 can range from 0-160 with the higher score indicating the worse condition. A Responder is defined as a participant with at least 20% improvement in UPDRS2+3 from Baseline to Week 26 (End of Part 1 Treatment); a participant with at least a 20% decrease from Baseline score in UPDRS2+3 is defined as a responder. The proportion of Responders was analyzed using a generalized linear mixed model with treatment effect, strata and Baseline UPDRS2+3 as a covariate, and treatment-by-time interaction as fixed effects and subject as random effect. (NCT01155479)
Timeframe: Baseline and Week 26

Intervention	Percentage of Responders (Number)
Preladenant 2 mg (Part 1)	25.90
Preladenant 5 mg (Part 1)	29.50
Preladenant 10 mg (Part 1)	31.50
Placebo (Part 1)	35.20
Rasagiline (Part 1)	33.10

CGI-S

Change from baseline in individual Clinical Global Impression - Severity. Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness (Parkinson's Disease) at the time of assessment relative to the clinician's past experience with patients who have the same diagnosis as one of the following:. 1 is normal and 7 is the most extremely ill patients. A subject defined as a treatment responder when the improvement from baseline to the Week12 / Last Observed Value (LOV) was of at least 1 point or more. (NCT01968460)
Timeframe: 12 weeks

Intervention	Participants (Count of Participants)
P2B001 Treatment A	13
P2B001 Treatment B	9
Placebo	3

PDQ39

Change from baseline in individual Parkinson's Disease Questionnaire - 39. Score 0-100 where 0 is indicative of no problem at all and 100 is the maximum level of problem. (NCT01968460)
Timeframe: 12 weeks

Intervention	units on a scale (Least Squares Mean)
P2B001 Treatment A	-3.01
P2B001 Treatment B	-2.19
Placebo	0.26

Total UPDRS I, II, III Scores

"Change from baseline to final visit (week 12) in total UPDRS score (defined as sum of parts I, II and III, scores (0-176). UPDRS- Unified Parkinson's Disease Rating Scale, minimum value is 0 points and maximum value is 176.~High score mean worse outcome." (NCT01968460)
Timeframe: Week 12

Intervention	units on a scale (Least Squares Mean)
P2B001 Treatment A	-5.97
P2B001 Treatment B	-5.15
Placebo	-1.31

UPDRS ADL (Part II)

Change from baseline in individual UPDRS ADL (part II). Activity of daily Life UPDRS part II minimum is 0 point and max is 52 point (worse outcome) (NCT01968460)
Timeframe: Week 12

Intervention	units on a scale (Least Squares Mean)
P2B001 Treatment A	-1.49
P2B001 Treatment B	-1.06
Placebo	0.36

UPDRS Motor (Part III)

Change from baseline in individual UPDRS motor (part III). UPDRS- Unified Parkinson's Disease Rating Scale, part III motor . min is 0 and Max is 108 (Worse outcome) (NCT01968460)
Timeframe: 12 weeks

Intervention	units on a scale (Mean)
P2B001 Treatment A	-4.43
P2B001 Treatment B	-3.95
Placebo	-1.62

Change in Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline to Last Observed Value in the Placebo Phase

Subjects were assessed according to the United Parkinson's Disease Rating Scale UPDRS,(version 3;) Parts I and II are historical data and are designed to rate mentation, behavior and mood; Part III is done as a motor examination at the time of a visit. The UPDRS measures patient status on a scale 0, which is normal or none, to 4, which is severe or the worst scenario. (NCT00256204)
Timeframe: 36 weeks

Intervention	Scores on a scale (Mean)
1mg Delayed Start	3.9
1mg Early Start	1.0
2mg Early Start	0.8

Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline

The primary efficacy endpoint was defined as the change in Total UPDRS from Baseline. Subjects were assessed according to the United Parkinson's Disease Rating Scale (UPDRS,(version 3;) Parts I and II are historical data and are designed to rate mentation, behavior and mood; Part III is done as a motor examination at the time of a visit. The UPDRS measures patient status on a scale 0, which is normal or none, to 4, which is severe or the worst scenario. (NCT00256204)
Timeframe: 12w, 24w, 36w, 42w, 48w, 54w, 60w, 66w, 72w

,,,

Intervention	Scores on a scale (Mean)
	Week 12	Week 24	Week 36	Week 42	Week 48	Week 54	Week 60	Week 66	Week 72
1mg Delayed Start	0.9	3.0	3.7	2.4	1.9	1.9	1.9	2.5	3.3
1mg Early Start	-1.2	-1.1	0.6	0.2	0.7	0.7	1.1	1.5	1.9
2mg Delayed Start	0.7	2.2	3.0	1.7	1.4	1.1	1.6	2.0	2.3
2mg Early Start	-0.7	-0.5	0.8	0.4	0.5	0.8	1.2	1.5	2.2

Change From Baseline to End of Week 12 Visit in ADL Subscale of PDQ39

"The efficacy of P2B 0.6/0.75 mg as compared to Pramipexole ER tablet titrated to optimal dose.~ADL PDQ39- Activity of daily life part in Parkinson's Disease Questionaries' 39 Score 0-100 when 100 is the worse outcome" (NCT03329508)
Timeframe: Baseline to week 12

Intervention	score on a scale (Least Squares Mean)
P2B001	-5.30
Rasagiline Capsule	-2.04
Pramipexole Capsule	-3.40
Pramipexole Extended Release	-3.12

Change From Baseline to Week 12 in Total UPDRS II ADL

Differences between of P2B 0.6/0.75 mg as compared to its individual components in the change of ADL UPDRS score (UPDRS part II) Activity of daily Life UPDRS part II minimum is 0 point and max is 52 point (worse outcome) (NCT03329508)
Timeframe: Baseline to week 12

Intervention	score on a scale (Least Squares Mean)
P2B001	-2.14
Rasagiline Capsule	-0.62
Pramipexole Capsule	-0.97
Pramipexole Extended Release	-2.02

Change From Baseline to Week 12 in Total UPDRS III Motor

"Differences between P2B 0.6/0.75 mg as compared to its individual components in the change of Motor UPDRS score (UPDRS Part III ).~UPDRS- Unified Parkinson's Disease Rating Scale, part III motor . min is 0 and Max is 108 (Worse outcome)" (NCT03329508)
Timeframe: baseline to week 12

Intervention	score on a scale (Least Squares Mean)
P2B001	-5.82
Rasagiline Capsule	-4.07
Pramipexole Capsule	-4.30
Pramipexole Extended Release	-6.36

Change in Epworth Sleepiness Scale (ESS) Score.

"Differences between P2B 0.6/0.75 mg as compared to pramipexole ER tablets in the change of Epworth Sleepiness Scale (ESS) score.~Scale is 0-24 , when 24 is worse outcome" (NCT03329508)
Timeframe: baseline to week 12

Intervention	score on a scale (Least Squares Mean)
P2B001	-0.33
Rasagiline Capsule	-0.81
Pramipexole Capsule	0.39
Pramipexole Extended Release	2.33

Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score (Defined as Sum of Parts II and III, Scores (0-160).

"Differences between P2B 0.6/0.75 mg as compared to its individual components in the change of total UPDRS score (defined as sum of parts II and III, scores (0-160).~UPDRS- Unified Parkinson's Disease Rating Scale, minimum value is 0 points and maximum value is 160.~High score mean worse outcome." (NCT03329508)
Timeframe: baseline to week 12

Intervention	score on a scale (Least Squares Mean)
P2B001	-7.98
Rasagiline Capsule	-4.69
Pramipexole Capsule	-5.32
Pramipexole Extended Release	-8.35

"Change From Baseline at Week 12 in Mean On Time Without Troublesome Dyskinesia"

"When a participant is on without dyskinesias, parkinsonian symptoms have dissipated and the participant is experiencing no uncontrollable extraneous movements. Study participants reported their parkinsonian symptoms at half-hour intervals as off, on without dyskinesia, on with non-troublesome dyskinesia, on with troublesome dyskinesia, or asleep on their daily diary for 3 days before randomization and for the 3 days immediately before their Week-12 visit. The mean change from baseline in on without troublesome dyskinesia time was based on a constrained longitudinal data analysis with treatment, time, and treatment-by-time interaction as fixed effects and subject as random effect." (NCT01155466)
Timeframe: Baseline and Week 12

Intervention	Hours/day (Mean)
Preladenant 2 mg	0.8
Preladenant 5 mg	0.9
Preladenant 10 mg	0.5
Placebo	0.4
Rasagiline 1 mg	0.7

"Change From Baseline in Mean Off Time"

"The on state is defined as the period of time during which a patient's symptoms of PD improve or disappear following treatment with L-dopa or dopamine agonists. The off state is defined as the period of time characterized by the return of symptoms (i..e. tremor, slowness, and rigidity) following treatment with L-dopa or dopamine agonists. Study participants reported their symptoms at half-hour intervals as off, on, or asleep on their daily diary for 3 days before randomization (baseline) and for the 3 days immediately before their Week-12 visit. The mean change from baseline in off time was based on a constrained longitudinal data analysis with treatment, time, and treatment-by-time interaction as fixed effects and subject as random effect." (NCT01155466)
Timeframe: Baseline and Week 12

Intervention	Hours/day (Mean)
Preladenant 2 mg	-0.9
Preladenant 5 mg	-0.9
Preladenant 10 mg	-0.8
Placebo	-0.8
Rasagiline 1 mg	-1.1

"Percentage of Participants With >30% Change (Reduction) From Baseline at Week 12 in Mean Off Time"

"The on state is defined as the period of time during which a patient's symptoms of PD improve or disappear following treatment with L-dopa or dopamine agonists. The off state is defined as the period of time characterized by the return of symptoms (i..e. tremor, slowness, and rigidity) following treatment with L-dopa or dopamine agonists. Study participants reported their symptoms at half-hour intervals as off, on, or asleep on their daily diary for 3 days before randomization and for the 3 days immediately before their Week-12 visit." (NCT01155466)
Timeframe: Baseline and Week 12

Intervention	Percentage of participants (Number)
Preladenant 2 mg	30.4
Preladenant 5 mg	33.6
Preladenant 10 mg	35.1
Placebo	32.8
Rasagiline 1 mg	33.9

Change From Baseline at Week 12 in Epworth Sleepiness Scale (ESS)

Intervention	Scores on a scale (Mean)
Preladenant 2 mg	-0.3
Preladenant 5 mg	-0.1
Preladenant 10 mg	0.0
Placebo	-0.3
Rasagiline 1 mg	0.1

Number of Participants With Alanine Aminotransferase >=3 Times the Upper Limit of Normal

The number of participants with alanine aminotransferase >=3 times the upper limit of normal and a >=10% increase was reported. (NCT01155466)
Timeframe: Up to Week 14

Intervention	Participants (Number)
Preladenant 2 mg	1
Preladenant 5 mg	1
Preladenant 10 mg	1
Placebo	1
Rasagiline 1 mg	0

Number of Participants With Aspartate Aminotransferase >=3 Times the Upper Limit of Normal

The number of participants with aspartate aminotransferase >=3 times the upper limit of normal and a >=10% increase was reported. (NCT01155466)
Timeframe: Up to Week 14

Intervention	Participants (Number)
Preladenant 2 mg	1
Preladenant 5 mg	1
Preladenant 10 mg	1
Placebo	0
Rasagiline 1 mg	0

Number of Participants With Diastolic Blood Pressure >=105 mm Hg

The number of participants with Diastolic Blood Pressure >=105 mm Hg was reported. (NCT01155466)
Timeframe: Up to Week 14

Intervention	Participants (Number)
Preladenant 2 mg	3
Preladenant 5 mg	4
Preladenant 10 mg	9
Placebo	7
Rasagiline 1 mg	4

Numberof Participants With Systolic Blood Pressure >=180 mm Hg

The number of participants with Systolic Blood Pressure >=180 mm Hg was reported. (NCT01155466)
Timeframe: Up to Week 14

Intervention	Participants (Number)
Preladenant 2 mg	1
Preladenant 5 mg	1
Preladenant 10 mg	3
Placebo	1
Rasagiline 1 mg	0

Percentage of Participants With Suicidality

The percentage of participants with suicidality using the Columbia - Suicide Severity Rating Scale (C-SSRS) was reported. The C-SSR was used in this study only for the purpose of safety monitoring by measuring the incidence of different types of suicidality categories during treatment. The assessment was done by the nature of the responses, not by a numbered scale. Participants who reported at least one occurrence of suicidal behavior or suicidal ideation were counted as having experienced suicidality. Suicidal behavior included suicide attempt, aborted attempt, interrupted attempt, or preparatory behavior. Suicidal ideation included a wish to die or active suicidal thought with or without method, intent or plan. (NCT01155466)
Timeframe: Up to Week 12

Intervention	Percentage of participants (Number)
Preladenant 2 mg	2.6
Preladenant 5 mg	2.6
Preladenant 10 mg	0.7
Placebo	3.2
Rasagiline 1 mg	0.6

Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)

The primary outcome measure is the difference in the rate of decline in function, as detected by the ALS Functional Rating Scale - Revised (ALSFRS-R) in patients taking rasagiline compared to a database of patients from randomized clinical trials conducted during 1997-2007. Minimum score is 0 (no function) to Maximum score is 48 (normal function) (NCT01232738)
Timeframe: up to 12 months

Intervention	units on a scale (Mean)
ALSRFS-R Slope - Rasagiline	-1.20
ALSFRS-R - Historical Placebo Control	-0.94

Change in BCL2/BAX Mitochondrial Biomarkers

The 12 month change in mitochondrial biomarker BCL2/BAX. We measured at baseline, 6 months and 12 months. (NCT01232738)
Timeframe: Baseline, 6 months, 12 months

Intervention	Ratio (Mean)
Rasagiline	0.24

Change in JC-1 Mitochondrial Biomarkers

The 12 month change in mitochondrial biomarkerJC-1 red/green fluorescence ratio. We measured at baseline, 6 months and 12 months. (NCT01232738)
Timeframe: Baseline, 6 months, 12 months

Intervention	ratio (Mean)
Rasagiline	1.92

Change in Mitotracker Mitochondrial Biomarkers

The 12 month change in mitochondrial biomarkerMitotracker. We measured at baseline, 6 months and 12 months. (NCT01232738)
Timeframe: Baseline, 6 months, 12 months

Intervention	Relative Fluorescent Intensity (Mean)
Rasagiline	54.14

Change in ORAC Mitochondrial Biomarkers

The 12 month change in mitochondrial biomarker Oxygen Radical Antioxidant Capacity. We measured at baseline, 6 months and 12 months. (NCT01232738)
Timeframe: Baseline, 6 months, 12 months

Intervention	Trolox equivalents (Mean)
Rasagiline	1028.70

Change in ORAC Mitochondrial Biomarkers

The 12 month change in mitochondrial biomarker Oxygen Radical Antioxidant Capacity. We measured at baseline, 6 months and 12 months. (NCT01232738)
Timeframe: Baseline, 6 months, 12 months

Intervention	umol Trolox equivalents (Mean)
Rasagiline	1028.70

Change in Percent Annexin V Mitochondrial Biomarkers

The 12 month change in mitochondrial biomarker Annexin V %. We measured at baseline, 6 months and 12 months. (NCT01232738)
Timeframe: Baseline, 6 months, 12 months

Intervention	Annexin V % (Mean)
Rasagiline	-6.67

Difference in Time to Treatment Failure

This group is defined as death, endotracheal intubation, tracheostomy-assisted ventilation or use of noninvasive ventilation >= 23 hours/day for 14 days or more. (NCT01232738)
Timeframe: up to 12 months

Intervention	years (Median)
Difference in Time to Treatment Failure - Rasagiline	0.9367
Difference in Time to Treatment Failure - Historical Control	0.8963

Change in Blood Oxygen Level-dependent(BOLD) Signal in the Posterior Putamen, M1, and Supplementary Motor Area(SMA).

12-month study in PD to watch the effect of an MAO-B inhibitor on BOLD signal in the posterior putamen, M1, and SMA. (NCT02789020)
Timeframe: Baseline and one-year

Intervention	arbitrary units (A.U.s) (Mean)
Rasagiline	-0.054
Placebo	-0.086

Change in Free-water Accumulation in the Substantia Nigra

"12-month study in PD to watch the effect of an Monoamine Oxidase-B inhibitor on the progressive increase of free-water accumulation in the substantia nigra.~Recently, free-water diffusion MRI analysis using a bi-tensor model was developed to explicitly estimate the contribution of freely diffusing water molecules within the voxel. This free-water measure is expected to increase with atrophy-based neurodegeneration. Since substantia nigra degeneration occurs mostly in the posterior region of the substantia nigra in PD (ie. ventrolateral tier), we tested the hypothesis that free-water would be elevated in the posterior substantia nigra of PD." (NCT02789020)
Timeframe: Baseline and one-year

Intervention	arbitrary units (A.U.s) (Mean)
Rasagiline	0.0009
Placebo	0.0041

Changes Between the Groups on fMRI

Participants will use their hand to squeeze an MRI compatible grip force transducer in the MRI unit. (NCT02789020)
Timeframe: Changes from baseline to 1 year

Intervention	unitless (Mean)
Rasagiline	-0.054
Placebo	-0.086

Changes in Parkinson's Disease Motor Symptoms and Bradykinesia

Motor testing batteries such as the Purdue Pegboard Test will be administered to measure changes in the progression of the PD motor symptoms and bradykinesia. (NCT02789020)
Timeframe: Baseline and one-year

Intervention	count of pegs (Mean)
Rasagiline	1.04
Placebo	0.689

Change From Baseline in Mean Total Daily OFF Time Using Parkinson's Disease Patient Diary

"Parkinson's Disease Patient Diary is a self-administered diary designed to assess motor fluctuations throughout the day. It is divided into 30-minute intervals, and the patient selects one of four options for each interval: asleep; off; on with no dyskinesia or without troublesome dyskinesia; or on with troublesome dyskinesia.~The Change From Baseline in Mean Total Daily OFF time is calculated by taking the difference between the average of the total daily OFF time at Weeks 4, 8, 12, and 16, and the Baseline Total Daily OFF Time." (NCT01479530)
Timeframe: Baseline and Weeks 4, 8, 12, and 16

Intervention	hours (Mean)
Placebo	-0.76
Azilect®	-1.25

Change From Baseline in UPDRS Motor Score During ON Time

UPDRS is a 42-item rating scale designed to assess Parkinson's Disease-related disability and impairment using a patient interview and a physical examination. It has 4 parts and 4 subsection scores. A higher score indicates a worse outcome. I: mentation, behaviour and mood symptoms - 0 to 16; II: ADL - 0 to 52; III: motor function - 0 to 108; IV: complications of dopaminergic therapy - 0 to 23. Subsection scores for I to III are used to calculate a total score that ranges from 0 (no disability) to 176 (total dependence). (NCT01479530)
Timeframe: Baseline and Week 16

Intervention	units on a scale (Mean)
Placebo	-1.75
Azilect®	-3.34

Change From Baseline in UPDRS-ADL Score During OFF Time

Unified Parkinson's Disease Rating Scale (UPDRS) is a 42-item rating scale designed to assess Parkinson's Disease-related disability and impairment using a patient interview and a physical examination. It has 4 parts and 4 subsection scores. A higher score indicates a worse outcome. I: mentation, behaviour and mood symptoms - 0 to 16; II: activities of daily living (ADL) - 0 to 52; III: motor function - 0 to 108; IV: complications of dopaminergic therapy - 0 to 23. Subsection scores for I to III are used to calculate a total score that ranges from 0 (no disability) to 176 (total dependence). (NCT01479530)
Timeframe: Baseline and Week 16

Intervention	units on a scale (Mean)
Placebo	-1.20
Azilect®	-2.21

Clinical Status Using CGI-I Score During ON Time

Clinical Global Impression - Global Improvement (CGI-I) is a single-item rating scale used to evaluate a patient's condition relative to baseline on a 7-point scale, regardless of whether the improvement is related to the investigational medicinal product (IMP). The scale ranges from 1 (very much improved) to 7 (very much worse). (NCT01479530)
Timeframe: Week 16

Intervention	units on a scale (Mean)
Placebo	3.56
Azilect®	3.15

Change in Negative Symptoms

"The Scale for the Assessment of Negative Symptoms (SANS) rating scale was used to assess the negative symptoms of schizophrenia. Scores on the subscales are combined (summed) to compute a total score. There are a total of 17 subscales. Each subscale ranges from 0=Not at all to 5=Severe. Every 4 weeks the summed subscale scores provide a total score for that week (0-85). Higher scores indicate more severe negative symptoms." (NCT00492336)
Timeframe: Every 4 weeks over a 12 week period

Intervention	units on a scale (Mean)
	Week 0	Week 4	Week 8	Week 12
Inactive Pill	33.5	32.3	34.1	34.3
Rasagiline	32.7	31.2	31.1	29.9

Change in Persistent Positive Symptoms

"The Brief Psychiatric Rating Scale (BPRS) positive symptom item total score was used to assess positive symptom change. The BPRS positive symptom items are: conceptual disorganization, hallucinatory behavior, unusual thought content, and suspiciousness. The total score is calculated by adding the scores for each item. Each scale ranges from 1=Not Present to 7=Very Severe. The minimum score is 4 and the maximum score is 28. A higher score indicates a more severe positive symptom rating." (NCT00492336)
Timeframe: Every 4 weeks for 12 weeks.

Intervention	units on a scale (Mean)
	Week 0	Week 4	Week 8	Week 12
Inactive Pill	9.1	9.1	9.8	8.9
Rasagiline	8.8	9.2	9.2	8.3

Cognitive Testing - Delayed Discounting

The monetary choice questionnaire for hypothetical monetary rewards was used to assess delayed discounting (Kirby et al, 1999). The measure includes 27 items in which participants choose between a smaller, immediate reward (SIR) and a larger, delayed reward (LDR). There are three LDR sizes: small ($25-35), medium ($50-60) and large ($75-85). By examining the pattern of choices that participants make across the set of 27 items it is possible to calculate their delay discounting rate, termed K. The discount rate determines the steepness of the reduction in the present value of a reward with increases in the delay to the possible receipt of that reward. Thus, higher values in K represent greater discounting of the value of future rewards. With this measure K values can range between a low of 0.00016 to a high of 0.25. Higher K values have been linked to measures of impulsivity. Shown in the table are the K values observed when the future rewards were small, medium, or large. (NCT00492336)
Timeframe: Beginning of treatment phase (week 0) and end of treatment phase (week 12)

Intervention	units on a scale (Geometric Mean)
	Large Reward: Week 0	Large Reward: Week 12	Medium Reward: Week 0	Medium Reward: Week 12	Small Reward: Week 0	Small Reward: Week 12
Inactive Pill	0.018	0.010	0.024	0.011	0.023	0.014
Rasagiline	0.004	0.010	0.003	0.008	0.009	0.016

Cognitive Testing - N-Back Neurocognitive Task

The N-Back task is a sequential letter working memory task. D-prime was used to measure accuracy on the 0-back, 1-back, and 2-back conditions. D-prime scores range from 0 to 8.6. Higher scores are better. As memory load increases from 0 to 1, from 1 to 2, D-prime scores are expected to be lower. (NCT00492336)
Timeframe: Beginning of treatment phase (week 0) and end of treatment phase (week 12)

Intervention	units on a scale (Mean)
	0-Back: Week 0	0-Back: Week 12	0-Back: Change	1-Back: Week 0	1-Back: Week 12	1-Back: Change	2-Back: Week 0	2-Back: Week 12	2-Back: Change
Inactive Pill	3.52	3.66	0.14	2.63	2.66	0.03	1.56	1.57	0.01
Rasagiline	3.47	3.79	0.32	2.75	2.96	0.20	1.75	1.59	-0.16

Cognitive Testing - Probabilistic Learning Task

To assess reward learning, participants used performance feedback to choose the most frequently rewarded item in each of three pairs of stimuli (one pair had reward probabilities: 80% vs 20%; one pair had reward probabilities of 70% vs 30%; one pair had the probabilities of 60% vs 40 %) (PL; Frank et al, 2004). A total of 240 trials were administered so each pair was seen 80 times. Higher scores represent more frequent choices of the optimal stimulus in each pair. The frequencies with which participants repeated an item choice that was rewarded on the previous presentation (win-stay) is also presented as a percentage. Similarly, the lose-shift score is the percentage of times that participants changed their choice for unrewarded items (lose-shift). The win-stay score serves as a measure of the impact of positive feedback on subsequent choices while the lost-shift score serves as a measure of the impact of negative feedback on subsequent choices. (NCT00492336)
Timeframe: Beginning of treatment phase (week 0) and end of treatment phase (week 12)

Intervention	percentage of optimal stimuli chosen (Mean)
	80 vs 20: Week 0	80 vs 20: Week 12	80 vs 20: Change	70 vs 30: Week 0	70 vs 30: Week 12	70 vs 30: Change	60 vs 40: Week 0	60 vs 40: Week 12	60 vs 40: Change	Lose Shifts: Week 0	Lose Shifts: Week 12	Lose Shifts: Change	Win Stays: Week 0	Win Stays: Week 12	Win Stays: Change
Inactive Pill	69.1	68.5	-0.7	66.1	65.9	-0.2	57.9	58.6	0.7	56.5	54.8	-1.2	62.2	64.4	2.3
Rasagiline	70.8	70.4	-0.4	69.7	64.4	-5.3	53.9	58.7	4.7	48.6	50.1	2.9	64.6	62.9	-1.7

Cognitive Testing - Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Score

The RBANS is a brief, individually administered test designed to evaluate neuropsychological status of adults, ages 20-89. The 12 subtests measure attention, language, visuospatial/constructional abilities, and immediate and delayed memory. The raw scores from the subtests are scaled together to create index scores, and these are summed for conversion to a total scale score. Higher score equals a better outcome. The total index score range for the RBANS is 40-160. (NCT00492336)
Timeframe: Beginning of treatment phase (week 0) and end of treatment phase (week 12)

Intervention	units on a scale (Mean)
	Week 0	Week 12	Change
Inactive Pill	74.2	75.3	1.1
Rasagiline	76.8	78.7	1.9

Depressive Symptoms

The Calgary Depression Scale (CDS; Addington et al, 1997) total score was used to assess depressive symptoms over the course of the study. Total scores were calculated by summing the scores of each of the 9 items. Total scores can range from 0-27, with higher scores indicating more severe depressive symptoms. (NCT00492336)
Timeframe: Every 4 weeks for 12 weeks.

Intervention	units on a scale (Mean)
	Week 0	Week 4	Week 8	Week 12
Inactive Pill	2.02	1.96	1.52	1.52
Rasagiline	2.29	2.19	2.31	2.58

Extrapyramidal Symptoms

The Simpson Angus Scale (SAS; Simpson and Angus, 1970) was used to assess extrapyramidal symptoms (EPS). The assessment consists of 11 items, each rating the severity of potential symptoms of movement disorders. Total scores are calculated by summing the scores of each of the 11 items for a potential total score of 0-44, with higher scores indicating more severe EPS. (NCT00492336)
Timeframe: Baseline (Week 0) and End of Study (Week 12)

Intervention	units on a scale (Mean)
	Week 0	Week 12	Change
Inactive Pill	1.93	1.89	-0.04
Rasagiline	1.82	0.96	-0.85

Global Change in Illness Severity

"The Clinical Global Impression (CGI) severity of illness item was used to assess global changes. Scores on this item range from 1=Normal, not at all ill to 7=Among the most extremely ill." (NCT00492336)
Timeframe: Every 4 weeks for 12 weeks.

Intervention	units on a scale (Mean)
	Week 0	Week 4	Week 8	Week 12
Inactive Pill	4.31	4.32	4.36	4.27
Rasagiline	4.05	4.08	1.00	1.08

Number of Participants Exhibiting Side Effects

"The Side Effect Checklist (SEC) was used to assess side effects. The SEC is comprised of 22 common side effects, which are rated on a 1 (none)-4 (severe) scale. Side effects are determined to be clinically significant if there is a two or more point increase in severity from baseline, or any side effect that receives a severity rating of 4 (severe) at any point in the treatment phase of the study." (NCT00492336)
Timeframe: Every week for 12 weeks

Intervention	Participants (Count of Participants)
	Abdominal Pain	Anorexia	Bruising Easily	Constipation	Diarrhea	Dizziness	Dry Mouth	Enuresis	Fever	Headache	Hypersalivation	Insomnia	Malaise	Mucosal Ulceration	Nausea	Rash	Restlessness	Sedation	Sore Throat	Stiffness	Tremor	Urticaria	Vomiting	Weight Loss
Inactive Pill	7	10	1	9	6	7	11	3	5	8	7	7	14	1	2	5	7	8	5	5	11	5	4	12
Rasagiline	5	7	4	12	9	5	7	4	2	7	4	2	8	1	6	3	4	8	3	7	3	3	4	10

Number of Participants With Akathisia

The Barnes Akathisia Scale (BAS; Barnes, 1989) was used to assess akathisia, a type of extrapyramidal symptom. The global clinical assessment of akathisia score is rated on a scale from 0=Absent to 5=Severe Akathisia. (NCT00492336)
Timeframe: Baseline and every two weeks throughout the double-blind phase of the study, for up to 12 weeks.

Intervention	Participants (Count of Participants)
	Score 0=Absent : Baseline	Score 0=Absent : End of Study	Score 1=Questionable : Baseline	Score 1=Questionable : End of Study	Score 2=Mild Akathisia : Baseline	Score 2=Mild Akathisia : End of Study	Score 3=Moderate Akathisia : Baseline	Score 3=Moderate Akathisia : End of Study
Inactive Pill	21	21	5	5	0	0	0	0
Rasagiline	20	20	3	2	2	3	1	1

Change From Baseline in Mean Total Daily OFF Time Using Parkinson's Disease Patient Diary

"Parkinson's Disease Patient Diary is a self-administered diary designed to assess motor fluctuations throughout the day. It is divided into 30-minute intervals, and the patient selects one of four options for each interval: asleep; off; on with no dyskinesia or without troublesome dyskinesia; or on with troublesome dyskinesia.~The Change From Baseline in Mean Total Daily OFF Time is calculated by taking the difference between the average of the total daily OFF time at Weeks 6, 10, 14 and 18, and the Baseline Total Daily OFF Time." (NCT01268891)
Timeframe: Baseline and Weeks 6, 10, 14, and 18

Intervention	hours (Mean)
Placebo	-1.24
Azilect®	-1.59

Change From Baseline in UPDRS Motor Score During ON Time

UPDRS is a 42-item rating scale designed to assess Parkinson's Disease-related disability and impairment using a patient interview and a physical examination. It has 4 parts and 4 subsection scores. A higher score indicates a worst outcome. I: mentation, behaviour and mood symptoms - 0 to 16; II: ADL - 0 to 52; III: motor function - 0 to 108; IV: complications of dopaminergic therapy - 0 to 23. Subsection scores for I to III are used to calculate a total score that ranges from 0 (no disability) to 176 (total dependence). (NCT01268891)
Timeframe: Baseline and Week 18

Intervention	units on a scale (Mean)
Placebo	-1.52
Azilect®	-2.87

Change From Baseline in UPDRS-ADL Score During OFF Time

Unified Parkinson's Disease Rating Scale (UPDRS) is a 42-item rating scale designed to assess Parkinson's Disease-related disability and impairment using a patient interview and a physical examination. It has 4 parts and 4 subsection scores. A higher score indicates a worst outcome. I: mentation, behaviour and mood symptoms - 0 to 16; II: activities of daily living (ADL) - 0 to 52; III: motor function - 0 to 108; IV: complications of dopaminergic therapy - 0 to 23. Subsection scores for I to III are used to calculate a total score that ranges from 0 (no disability) to 176 (total dependence). (NCT01268891)
Timeframe: Baseline and Week 18

Intervention	units on a scale (Mean)
Placebo	0.13
Azilect®	-0.57

Clinical Status Using CGI-I Score During ON Time

Intervention	units on a scale (Mean)
Placebo	3.35
Azilect®	3.05

AUC0-t - Area Under the Plasma Concentration-time Curve From Time 0 to Last Observed Concentration

(NCT01532141)
Timeframe: pre-dose, and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h post-dose

Intervention	ng.h/mL (Mean)
	BIA 9-1067	Rasagiline
BIA 9-1067 1h Before Rasagiline	2182	3277
BIA 9-1067 Alone	1966	NA
BIA 9-1067 Concomitant Rasagiline	2064	3370

Cmax - Maximum Observed Plasma Drug Concentration

(NCT01532141)
Timeframe: pre-dose, and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h post-dose

Intervention	ng/mL (Mean)
	BIA 9-1067	Rasagiline
BIA 9-1067 1h Before Rasagiline	703	4.260
BIA 9-1067 Alone	647	NA
BIA 9-1067 Concomitant Rasagiline	640	4.299

Time of Occurrence of Cmax (Tmax)

6-mL blood samples for the determination of plasma concentrations of BIA 9-1067 and/or rasagiline will be drawn by direct venipuncture or via an intravenous catheter into potassium ethylenediaminetetraacetic acid(EDTA)Vacutainers (NCT01532141)
Timeframe: pre-dose, and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h post-dose

Intervention	hours (Median)
	BIA 9-1067	Rasagiline
BIA 9-1067 1h Before Rasagiline	3.00	0.5
BIA 9-1067 Alone	3.00	NA
BIA 9-1067 Concomitant Rasagiline	2.50	0.5

Change From Baseline to Week 18 in the Unified Parkinson's Disease Rating Scale (UPDRS) Total Score for Part II - Activities of Daily Living

The UPDRS was developed as a comprehensive tool to monitor the impact of Parkinson's Disease and the degree of disability caused. UPDRS contains four parts, the second of which is reported in this outcome. Part II is the participants' evaluation of the disease's impact on normal activities. Part II contains a total of 13 questions, which are each rated on a scale of 0 (normal or no disease effect) to 4 (maximum negative effect), for a total scale of 0-52. Negative change from baseline values indicate improvement. (NCT01049984)
Timeframe: Day 0 (baseline), Week 18

Intervention	units on a scale (Least Squares Mean)
Rasagiline 1 mg	-0.1
Placebo	0.3

Change From Baseline to Week 18 in the Unified Parkinson's Disease Rating Scale (UPDRS) Total Score for Part III - Motor Function

"The UPDRS was developed as a comprehensive tool to monitor the impact of Parkinson's Disease and the degree of disability caused. Version 3 of UPDRS contains four parts, the third of which is reported in this outcome. Part III is a clinician's evaluation of motor function. Part III contains 14 questions, which are each rated on a scale of 0 (normal or no disease effect) to 4 (maximum negative effect), for a total scale of 0-56. Negative change from baseline values indicate improvement.~All site raters (medical doctor [MD], doctor of osteopathy [DO], nurse practitioner, or physician assistant) received training on how to complete the UPDRS. The same site rater completed the UPDRS at all visits" (NCT01049984)
Timeframe: Day 0 (baseline), Week 18

Intervention	units on a scale (Least Squares Mean)
Rasagiline 1 mg	-3.4
Placebo	-1.6

Change From Baseline to Week 18 in the Unified Parkinson's Disease Rating Scale (UPDRS) Total Score for Parts I, II and III

"The UPDRS was developed as a comprehensive tool to monitor the impact of Parkinson's Disease and the degree of disability caused. Version 3 of UPDRS contains four parts, three of which are totaled and reported in this outcome. Part I is a clinician's evaluation of mentation (mental activity or state of mind), cognition (ability to acquire knowledge), behaviour and mood. Part II is the participants' evaluation of the disease's impact on normal activities. Part III is a clinician's evaluation of motor function. Parts I, II, and III contain a total of 31 questions, which are each rated on a scale of 0 (normal or no disease effect) to 4 (maximum negative effect), for a total scale of 0-124. Negative change from baseline values indicate improvement.~All site raters (medical doctor [MD], doctor of osteopathy [DO], nurse practitioner, or physician assistant) received training on how to complete the UPDRS. The same site rater completed the UPDRS at all visits." (NCT01049984)
Timeframe: Day 0 (baseline), Week 18

Intervention	units on a scale (Least Squares Mean)
Rasagiline 1 mg	-3.6
Placebo	-1.2

Clinical Global Improvement (CGI) Score at Week 18 As Assessed by the Participant

CGI is used by the participant to rate his/her total improvement during the study. Specifically, participants are asked to compare their condition at the beginning of the study to his/her condition at Week 18, how much has he/she changed? Answers are 0 (not assessed), 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), 7(very much worse). (NCT01049984)
Timeframe: 18 weeks

Intervention	participants (Number)
	Not assessed (0)	Very much improved (1)	Much improved (2)	Minimally improved (3)	No change (4)	Minimally worse (5)	Much worse (6)	Very much worse (7)
Placebo	1	7	18	40	52	35	8	1
Rasagiline 1 mg	0	7	18	39	52	36	5	2

Clinical Global Improvement (CGI) Score at Week 18 As Assessed by the Site Rater

"CGI is used by the site rater to rate participants total improvement during the study whether or not, in the investigators' judgment, it is due entirely to drug treatment. Specifically, site raters are asked to compare the participants condition at the beginning of the study to his/her condition at Week 18, how much has he/she changed? Answers are 0 (not assessed), 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), 7(very much worse).~Site raters can be the medical doctor [MD], doctor of osteopathy [DO], nurse practitioner, or physician assistant." (NCT01049984)
Timeframe: 18 weeks

Intervention	participants (Number)
	Not assessed (0)	Very much improved (1)	Much improved (2)	Minimally improved (3)	No change (4)	Minimally worse (5)	Much worse (6)	Very much worse (7)
Placebo	1	5	20	39	53	42	1	1
Rasagiline 1 mg	0	5	21	45	63	21	3	1

Illness Severity Score at Day 0 and Week 18 As Assessed by the Site Rater

"Site raters were asked: Considering your total clinical experience with the particular population, how ill is the patient at this time? Answers were based on a 0-7 scale, with 0=not assessed, 1= normal, not at all ill, and 7= among the most extremely ill of patients.~Site raters can be the medical doctor [MD], doctor of osteopathy [DO], nurse practitioner, or physician assistant." (NCT01049984)
Timeframe: Day 0 (baseline), Week 18

Intervention	participants (Number)
	Day 0: Not assessed (0)	Day 0: Normal, not at all ill (1)	Day 0: Borderline ill (2)	Day 0: Mildly Ill (3)	Day 0: Moderately Ill (4)	Day 0: Markedly ill (5)	Day 0: Severely ill (6)	Day 0: Among the most extremely ill (7)	Week 18: Not assessed (0)	Week 18: Normal, not at all ill (1)	Week 18: Borderline ill (2)	Week 18: Mildly ill (3)	Week 18: Moderately ill (4)	Week 18: Markedly ill (5)	Week 18: Severely ill (6)	Week 18: Among the most extremely ill (7)
Placebo	0	5	26	100	28	2	0	0	2	5	33	89	31	1	1	0
Rasagiline 1 mg	0	4	18	95	39	1	0	0	0	10	28	90	29	2	0	0

Change From Baseline to Week 26 in Subscale Scores of the UPDRS (Part I)

The Unified Parkinson's Disease Rating Scale (UPDRS) Part I evaluates mentation, behaviour and mood symptoms, it comprises 4 parts and the score ranges from 0 (normal) to 16 (severe impairement) (NCT01556165)
Timeframe: Baseline to Week 26

Intervention	units on a scale (Mean)
Placebo	0.08
Rasagiline	-0.54

Change From Baseline to Week 26 in Subscale Scores of the UPDRS (Part II)

The Unified Parkinson's Disease Rating Scale (UPDRS) Part II evaluates activities of daily living, it comprises 13 parts and the score ranges from 0 (normal) to 52 (severe impairement and disability) (NCT01556165)
Timeframe: Baseline to Week 26

Intervention	units on a scale (Mean)
Placebo	0.25
Rasagiline	-0.43

Change From Baseline to Week 26 in Subscale Scores of the UPDRS (Part III)

The Unified Parkinson's Disease Rating Scale (UPDRS) Part III evaluates motor function, it comprises 14 parts and the score ranges from 0 (normal) to 108 (severe impairement and disability) (NCT01556165)
Timeframe: Baseline to Week 26

Intervention	units on a scale (Mean)
Placebo	-0.52
Rasagiline	-2.23

Change From Baseline to Week 26 in UPDRS Total Score

The Unified Parkinson's Disease Rating Scale (UPDRS) is a 42-item rating scale designed to assess Parkinson's disease-related disability and impairment. The scale comprises four parts: Part I evaluates mentation, behaviour, and mood symptoms; Part II evaluates activities of daily living (ADL); Part III evaluates motor function; and Part IV evaluates complications of dopaminergic therapy. The total score is the sum of the subscale scores for Parts I to III and ranges from 0 (no disability) to 176 (total dependence). (NCT01556165)
Timeframe: Baseline to Week 26

Intervention	units on a scale (Mean)
Placebo	-0.18
Rasagiline	-3.18

Change From Baseline to Week 24 in the Montreal Cognitive Assessment (MoCA) Score

The MoCA assesses 8 cognitive areas: visuospatial/executive, naming, memory, attention, language, abstraction, delayed recall, and orientation. Scores range from 0 (worst) to 30 (best). (NCT01723228)
Timeframe: Baseline to Week 24 (or early discontinuation)

Intervention	units on a scale (Least Squares Mean)
Rasagiline 1.0 mg/Day	0.9
Placebo	1.0

Change From Baseline to Week 24 in the Penn Daily Activities Questionnaire (PDAQ) Score

The PDAQ is a 15-item questionnaire that assesses the patient's difficulty with activities of daily living. The total score has a range of 0 (no impairment) to 60 (severe impairment). (NCT01723228)
Timeframe: Baseline to Week 24 (or early discontinuation)

Intervention	units on a scale (Least Squares Mean)
Rasagiline 1.0 mg/Day	-0.9
Placebo	-0.1

Change From Baseline to Week 24 in the Unified Parkinson's Disease Rating Scale (UPDRS), Motor Subscale (Part 3), Version 3, Score

UPDRS Part 3 (motor examination subscale) comprises 14 items assessing the motor disabilities of the patient at the time of the visit. The participant's speech, facial expressions, ability to arise from a chair (with arms folded), posture, gait, postural stability (retropulsion test), and body bradykinesia and hypokinesia are assessed. In addition, the following evaluations require assessment of the face, neck or extremities: tremor at rest, action or postural tremor of hands, rigidity, finger taps, hand movements (open and close), rapid alternating movements of hands (pronation and supination), and leg agility (tap heel on ground). This evaluation is performed while the participant is in the 'on' phase. Each item is assessed on a scale from 0 (normal, absent, or none) to 4 (severe impairment), which are summed to get the sub-scale score. The total scale is 0-57 with a higher score indicating more severe symptoms; a decrease in the scores indicates improvement. (NCT01723228)
Timeframe: Baseline to Week 24 (or early discontinuation)

Intervention	units on a scale (Least Squares Mean)
Rasagiline 1.0 mg/Day	-3.7
Placebo	-1.2

Change From Baseline to Week 24 in UPDRS, Activities of Daily Living (ADL) Subscale (Part 2), Version 3, Score

UPDRS Part 2 (ADL subscale) comprises 13 items evaluating the impact of PD on patients' ADL (in both the on and off states) in the week prior to the visit. The following 13 ADL are assessed: speech, salivation, swallowing, handwriting, cutting food and handling utensils, dressing, hygiene, turning in bed and adjusting bed clothes, falling (unrelated to freezing), freezing when walking, walking, tremor, and sensory complaints related to Parkinsonism. Each item is assessed on a scale from 0 (normal, absent, or none) to 4 (severe impairment), which are summed to get the sub-scale score. The total scale is 0-52 with a higher score indicating more severe symptoms; a decrease in the scores indicates improvement. (NCT01723228)
Timeframe: Baseline to week 24 (or early discontinuation)

Intervention	units on a scale (Least Squares Mean)
Rasagiline 1.0 mg/Day	-0.9
Placebo	1.4

Mean Change From Baseline to Week 24 in the Scales for Outcomes in Parkinson's Disease-Cognition (SCOPA-COG) Summary Score

The SCOPA-COG consists of evaluations in 4 domains: memory, attention, executive functioning, and visuospatial functioning.Scores range from 0 to 43, with higher scores reflecting better performance. (NCT01723228)
Timeframe: Baseline to Week 24 (or early discontinuation)

Intervention	units on a scale (Least Squares Mean)
Rasagiline 1.0 mg/Day	1.6
Placebo	0.8

Alzheimer's Disease Cooperative Study's Clinical Global Impression of Change Modified for Mild Cognitive Impairment (ADCS MCI-CGIC) Score at Week 24

The ADCS MCI-CGIC score is generated in the context of a semi-structured interview and is an indication of the change in the participant's global status, cognition, behavior, and functional abilities (FA) on a 7-point scale, with the best score being 'marked improvement' and the worst being 'marked worsening.' (NCT01723228)
Timeframe: Week 24 (or early discontinuation)

Intervention	participants (Number)
	CGIC: Marked improvement; n=78, 79	CGIC: Moderate improvement; n=78, 79	CGIC: Minimal improvement; n=78, 79	CGIC: No change; n=78, 79	CGIC: Minimal worsening; n=78, 79	CGIC: Moderate worsening; n=78, 79	CGIC: Marked worsening; n=78, 79	CGIC Cognition: Marked improvement; n=77, 79	CGIC Cognition: Moderate improvement; n=77, 79	CGIC Cognition: Minimal improvement; n=77, 79	CGIC Cognition: No change; n=77, 79	CGIC Cognition: Minimal worsening; n=77, 79	CGIC Cognition: Moderate worsening; n=77, 79	CGIC Cognition: Marked worsening; n=77, 79	CGIC Behavior: Marked improvement; n=76, 79	CGIC Behavior: Moderate improvement; n=76, 79	CGIC Behavior: Minimal improvement; n=76, 79	CGIC Behavior: No change; n=76, 79	CGIC Behavior: Minimal worsening; n=76, 79	CGIC Behavior: Moderate worsening; n=76, 79	CGIC Behavior: Marked worsening; n=76, 79	CGIC FA: Marked improvement; n=76, 79	CGIC FA: Moderate improvement; n=76, 79	CGIC FA: Minimal improvement; n=76, 79	CGIC FA: No change; n=76, 79	CGIC FA: Minimal worsening; n=76, 79	CGIC FA: Moderate worsening; n=76, 79	CGIC FA: Marked worsening; n=76, 79
Placebo	4	7	23	33	12	0	0	3	4	18	44	8	2	0	3	1	11	62	2	0	0	3	4	12	55	5	0	0
Rasagiline 1.0 mg/Day	1	9	11	42	14	1	0	0	9	15	41	9	3	0	0	4	11	54	7	0	0	0	5	13	44	12	2	0

ALS Functional Rating Scale-Revised (ALSFRS-R)

Difference in ALS Functional Rating Scale - Revised (ALSFRS-R) score. The ALSFRS-R is an ordinal rating scale that assesses 12 functional activities. Each activity is scored between 0-4, with a total score ranging from 48 (normal function) to 0 (no function). (NCT01786603)
Timeframe: ALS Functional Rating Scale-Revised (ALSFRS-R) Difference from Baseline to Month 12

Intervention	score on a scale (Mean)
Rasagiline	-1.00
Placebo	-1.26

Change in Quality of Life

Participants completed the single-item ALSQOL (ALS Quality of Life) which asks participants to rank their global quality of life, considering all parts of their lives - physical, emotional, social, spiritual and financial - in the last 7 days and rate on a scale of 0 (very bad) to 10 (excellent). (NCT01786603)
Timeframe: Quality of Life Change from Baseline to Month 12

Intervention	Score on a scale (Mean)
Rasagiline	-0.09
Placebo	-0.12

Change in Vital Capacity (VC)

Determine if decline in vital capacity is slower in participants taking 2 mg rasagiline than controls. (NCT01786603)
Timeframe: Vital Capacity Change from Baseline to Month 12

Intervention	Liters (Mean)
Rasagiline	-2.24
Placebo	-2.48

Difference in Survival Status Between Study Groups

Determine if there is a difference in survival between participants on rasagiline than patients not on rasagiline (NCT01786603)
Timeframe: Survival status at Month 12

Intervention	Participants (Count of Participants)
Rasagiline	55
Placebo	19

Effect of Study Drug on Apoptosis Markers

Effect of rasagiline on the apoptosis markers (Annexin V stain) in participants with ALS. Assessed at baseline, month 6, and month 12; change from baseline to month 12 reported. Extra time point was not a pre-specified Primary or Secondary Outcome Measure. (NCT01786603)
Timeframe: Apoptosis Marker change from Baseline to Month 12

Intervention	percentage of change (Mean)
Rasagiline	0.019
Placebo	0.02

Effect of Study Drug on Oxidative Stress

Determine if oxygen radical antioxidant capacity is targeted by rasagiline in participants with ALS. Assessed at baseline, month 6, and month 12; change from baseline to month 12 reported. Extra time point was not a pre-specified Primary or Secondary Outcome Measure. (NCT01786603)
Timeframe: Oxidative Stress change from Baseline to Month 12

Intervention	pmole/ml (Mean)
Rasagiline	0.14
Placebo	1.21

Number of Participants With Adverse Events

Determine if participants on rasagiline 2 mg had a different safety profile than patients not on rasagiline. Adverse event information to be collected from date of enrollment until end of study participation. (NCT01786603)
Timeframe: Adverse Events from Baseline to Month 12

Intervention	Participants (Count of Participants)
Rasagiline	28
Placebo	15

AUC0-t - Area Under the Plasma Concentration-time Curve From Time 0 to Last Observed Concentration

(NCT01532128)
Timeframe: pre-dose, and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h post-dose

Intervention	ng.h/mL (Mean)
	BIA 9-1067	Rasagiline
Rasagiline 1 h After BIA 9-1067	2133	4.431
Rasagiline Alone	NA	4.323
Rasagiline Concomitant BIA 9-1067	1980	4.391

Cmax - Maximum Observed Plasma Concentration

(NCT01532128)
Timeframe: pre-dose, and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h post-dose

Intervention	ng/mL (Mean)
	BIA 9-1067	Rasagiline
Rasagiline 1 h After BIA 9-1067	672	6.058
Rasagiline Alone	NA	6152
Rasagiline Concomitant BIA 9-1067	643	6.078

Tmax - Time of Occurrence of Cmax

(NCT01532128)
Timeframe: pre-dose, and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h post-dose

Intervention	hours (Median)
	BIA 9-1067	Rasagiline
Rasagiline 1 h After BIA 9-1067	2.00	0.50
Rasagiline Alone	NA	0.50
Rasagiline Concomitant BIA 9-1067	2.50	0.50

Change in ADAS-Cog 11 (Alzheimer's Disease Assessment Scale - Cognitive 11) Score

The ADAS-Cog 11 (Alzheimer's Disease Assessment Scale - Cognitive 11) is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis. A higher score indicates more impairment. Scores from the original portion of the test range from 0 (best) to 70 (worse). We used total ADAS-Cog 11 scores, which is a sum of individual subscales. We calculated the change by subtracting the ADAS Cog score at week 24 from baseline score. A positive change indicates cognitive worsening. (NCT02359552)
Timeframe: Mean change in scores from baseline to week 24

Intervention	score on a scale (Mean)
Placebo	2.76
Rasagiline	1.81

Change in ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living) Score

Measure Description: The ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living) is an activities-of-daily-living inventory developed by the ADCS to assess functional performance in participants with AD. Using a structured interview format, study partners are queried as to whether participants attempted each item in the inventory during the past 4 weeks and their level of performance. The ADCS-ADL provides a total score from 0-78, with a lower score indicating greater severity. We calculated change by subtracting scores on week 24 test from the baseline score. A negative score indicates worsening ability to complete ADLs. (NCT02359552)
Timeframe: Mean change in scores from baseline to week 24

Intervention	score on a scale (Mean)
Placebo	-3.23
Rasagiline	-3.75

Change in COWAT (Controlled Oral Word Association Test) Score

"Measure Description: Study participants are instructed, I want to see how many words you can say beginning with a certain letter in one minute. The study participant's responses are recorded on the worksheet. Study participants are then given an additional one minute for each of two different letters using similar instructions. The score is the total number of acceptable words for the three trials combined. A higher score represents better performance.~Responses are then judged for their acceptability (example for the use of proper nouns, numbers, repetitions and stem word with a different ending). The score is the total number of acceptable words for the three trials combined. A higher score represents better performance. We calculated change by subtracting week 24 scores from baseline scores. A negative score indicates worse performance." (NCT02359552)
Timeframe: Mean change in scores from baseline to week 24

Intervention	score on a scale (Mean)
Placebo	-1.09
Rasagiline	0.62

Change in Digit Span

Measure Description: The Digit Span consists of repetition of increasing long strings of digits presented at 1 per second as read by the examiner and repeated by the subject.The score is the maximum number of digits the patient can repeat until they fail twice in a row. The reverse digit span is identical to the forward digit span except that the patient repeats the presented digits in reverse order. The score is the maximum number of digits the patient can repeat in reverse order until they fail twice in a row. Each correct response is worth one point with a maximum total score of 28. A higher score is better. We calculated change by subtracting week 24 score from baseline score. A negative score indicates worse performance over the course of study. (NCT02359552)
Timeframe: Mean change in scores from baseline to week 24

Intervention	score on a scale (Mean)
Placebo	-1.18
Rasagiline	-0.29

Change in MMSE (Mini Mental Status Examination) Score

Measure Description: The MMSE (Mini Mental Status Examination) is a brief, frequently used screening instrument for AD drug studies. The MMSE evaluates orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two overlapping pentagons. A lower score indicates more cognitive impairment. The highest score is 30, range is between 0 (severe impairment) and 30 (cognitively normal). We calculated the change in scores by subtracting week 24 score from baseline. A negative score indicates clinical worsening. (NCT02359552)
Timeframe: Mean change in scores from baseline to week 24

Intervention	score on a scale (Mean)
Placebo	-1.14
Rasagiline	-0.65

Change in NPI (Neuropsychiatric Inventory) Score

Measure Description: The behavioral outcome measure for this trial is the NPI (Neuropsychiatric Inventory). The NPI evaluates both the frequency and severity of 10 neuropsychiatric disturbances. Frequency assessments range from 1 (occasionally, less than once per week) to 4 (very frequently, once or more per day or continuously) as well as severity (1=mild, 2=moderate, 3=severe). The overall score is calculated by summing the severity and frequency of the subscale measures. The range of scores is 0-40. A score of 0 indicates no behavioral impairment and a score of 40 indicates severe behavioral impairment. We calculated change by subtracting Week 24 scores from baseline scores. A positive change indicates behavioral worsening. (NCT02359552)
Timeframe: Mean change in scores from baseline to week 24

Intervention	score on a scale (Mean)
Placebo	2
Rasagiline	0.2

Change in QoL-AD (Quality of Life - Alzheimer's Disease) Score

Measure Description: The QoL-AD (Quality of Life - Alzheimer's Disease) is a commonly used 13 item QoL scale that assesses items specific to QoL in patients with cognitive impairment. It is administered to the research partner with answers for the patient. Points are assigned to each item as follows: poor = 1, fair = 2, good = 3, excellent = 4.The total score is the sum of all 13 items. The range of score is from 0-52. We calculated the change by subtracting the scores on week 24 score from baseline. A negative value indicates worsening quality of life. (NCT02359552)
Timeframe: This assessment will be performed at the Baseline and Week 24 visits.

Intervention	score on a scale (Mean)
Placebo	-1.95
Rasagiline	1.11

Change in Regional Glucose Metabolism Between Week 24 and Baseline as Measured by 18F-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET).

The primary outcome measure is the change from baseline to week 24 in FDG-PET as measured by Standard Uptake Units Regional (SUVR) in several pre-specified brain regions including the medial temporal, lateral temporal, posterior cingulate - precuneus, inferior parietal, middle frontal, anterior cingulate, and striatum. The SUVR change was calculated by subtracting the value at 24 weeks from baseline values. Negative values indicate increased hypometabolism (i.e. worsening of cell function). (NCT02359552)
Timeframe: 24 weeks

Intervention	SUVR (Mean)
	Middle Frontal	Anterior Cingulate	Superior Frontal	Striatum	Medial Temporal	Lateral Temporal	Post Cingulate - Precuneus	Inferior Parietal
Placebo	-0.032	-0.020	-0.016	-0.024	-0.015	-0.020	-0.017	-0.025
Rasagiline	-0.011	-0.003	-0.003	-0.002	-0.010	-0.016	-0.016	-0.018

Article	Year
Safety comparisons among monoamine oxidase inhibitors against Parkinson's disease using FDA adverse event reporting system. Scientific reports, 11-06, Volume: 13, Issue: 1	2023
Effectiveness and safety of safinamide in the Toledo Movement Disorders Unit. Revista de neurologia, 10-31, Volume: 77, Issue: S03	2023
Safety and Effectiveness of Rasagiline in Chinese Patients with Parkinson's Disease: A Prospective, Multicenter, Non-interventional Post-marketing Study. Drug safety, Volume: 46, Issue: 7	2023
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled European journal of neurology, Volume: 30, Issue: 4	2023
Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson's disease population: an open-label, levodopa add-on study. Acta neurologica Belgica, Volume: 123, Issue: 3	2023
Overnight switch from rasagiline to safinamide in Parkinson's disease patients with motor fluctuations: a tolerability and safety study. European journal of neurology, Volume: 28, Issue: 1	2021
Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), Volume: 127, Issue: 2	2020
Pharmacokinetics, Pharmacodynamics, and Safety of a Single Escalating Dose and Repeated Doses of Rasagiline Transdermal Patch in Healthy Chinese Subjects. Clinical pharmacology in drug development, Volume: 9, Issue: 5	2020
Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), Volume: 126, Issue: 3	2019
Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced α-synuclein aggregation and toxicity: Implication for Parkinson neuroprotective therapy. European journal of pharmacology, Feb-15, Volume: 845	2019
Pharmacokinetics and safety of single and multiple doses of rasagiline in healthy Japanese and caucasian subjects. Basic & clinical pharmacology & toxicology, Volume: 124, Issue: 3	2019
Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. The Lancet. Neurology, Volume: 17, Issue: 8	2018
Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study. Parkinsonism & related disorders, Volume: 53	2018
Pharmacokinetics, Pharmacodynamics, and Safety of Rasagiline Transdermal Patch: A Preliminary Study in Healthy Chinese Subjects. Clinical drug investigation, Volume: 38, Issue: 2	2018
Safety and efficacy of rasagiline in addition to levodopa for the treatment of idiopathic Parkinson's disease: a meta-analysis of randomised controlled trials. European neurology, Volume: 73, Issue: 1-2	2015
Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). Pharmacotherapy, Volume: 34, Issue: 12	2014
Protective effect of rasagiline in aminoglycoside ototoxicity. Neuroscience, Apr-18, Volume: 265	2014
Cardiac safety of rasagiline, a selective monoamine oxidase type B inhibitor for the treatment of Parkinson's disease: a thorough QT/QTc study. International journal of clinical pharmacology and therapeutics, Volume: 52, Issue: 3	2014
Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease. Expert opinion on drug safety, Volume: 12, Issue: 4	2013
Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial. The international journal of neuropsychopharmacology, Volume: 16, Issue: 7	2013
Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease. Current medical research and opinion, Volume: 29, Issue: 1	2013
Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline. The International journal of neuroscience, Volume: 122, Issue: 7	2012
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS computational biology, Volume: 7, Issue: 12	2011
Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease. European journal of neurology, Volume: 19, Issue: 2	2012
Safety of rasagiline for the treatment of Parkinson's disease. Expert opinion on drug safety, Volume: 10, Issue: 4	2011
Site-activated chelators derived from anti-Parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer's disease. Neurochemical research, Volume: 35, Issue: 12	2010
TVP1022 and propargylamine protect neonatal rat ventricular myocytes against doxorubicin-induced and serum starvation-induced cardiotoxicity. Journal of cardiovascular pharmacology, Volume: 52, Issue: 3	2008
Safety of rasagiline in elderly patients with Parkinson disease. Neurology, May-09, Volume: 66, Issue: 9	2006
Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy, Volume: 24, Issue: 10	2004
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. Journal of neural transmission (Vienna, Austria : 1996), Volume: 108, Issue: 8-9	2001
Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. European journal of pharmacology, Oct-22, Volume: 116, Issue: 3	1985
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Isradipine, an L-type calcium channel inhibitor, attenuates cue-associated methamphetamine-seeking in mice. Brain research, 11-01, Volume: 1818	2023
Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease. Neuromolecular medicine, Volume: 21, Issue: 3	2019
Rasagiline, an inhibitor of MAO-B, decreases colonic motility through elevating colonic dopamine content. Neurogastroenterology and motility, Volume: 30, Issue: 11	2018
Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study. Journal of neurology, Volume: 264, Issue: 6	2017
Free-water and BOLD imaging changes in Parkinson's disease patients chronically treated with a MAO-B inhibitor. Human brain mapping, Volume: 37, Issue: 8	2016
Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cellular and molecular neurobiology, Volume: 21, Issue: 6	2001
Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. British journal of pharmacology, Volume: 132, Issue: 2	2001
Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline. Mechanisms of ageing and development, Jul-31, Volume: 116, Issue: 2-3	2000
Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. Journal of neurochemistry, Volume: 67, Issue: 4	1996
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Preparation and Archives of Razi Institute, Volume: 78, Issue: 3	2023
Thin film hydration versus modified spraying technique to fabricate intranasal spanlastic nanovesicles for rasagiline mesylate brain delivery: Characterization, statistical optimization, and in vivo pharmacokinetic evaluation. Drug delivery and translational research, Volume: 13, Issue: 4	2023
Influence of chitosan thioglycolic acid conjugate in improving bioavailability of an antiparkinson drug; Rasagiline Mesylate from transdermal patch. Drug development and industrial pharmacy, Volume: 47, Issue: 6	2021
Microemulsion-based gel for the transdermal delivery of rasagiline mesylate: In vitro and in vivo assessment for Parkinson's therapy. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Volume: 165	2021
Impact of rasagiline nanoparticles on brain targeting efficiency via gellan gum based transdermal patch: A nanotheranostic perspective for Parkinsonism. International journal of biological macromolecules, Dec-01, Volume: 164	2020
Pharmacokinetic interaction study between flavanones (hesperetin, naringenin) and rasagiline mesylate in wistar rats. Drug development and industrial pharmacy, Volume: 42, Issue: 7	2016
Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route. Drug delivery, Volume: 23, Issue: 1	2016
Nasal in-situ gels for delivery of rasagiline mesylate: improvement in bioavailability and brain localization. Drug delivery, Volume: 22, Issue: 7	2015
Comparative single-dose pharmacokinetics of rasagiline in minipigs after oral dosing or transdermal administration via a newly developed patch. Xenobiotica; the fate of foreign compounds in biological systems, Volume: 43, Issue: 8	2013
Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Pharmacotherapy, Volume: 27, Issue: 12 Pt 2	2007
Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors. Drugs & aging, Volume: 24, Issue: 8	2007
Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors. Expert review of neurotherapeutics, Volume: 5, Issue: 6	2005
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Efficacy of rasagiline monotherapy for early Parkinson disease: A systematic review and meta-analysis of randomized controlled trials. Journal of psychopharmacology (Oxford, England), Volume: 36, Issue: 6	2022
P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease. Advances in therapy, Volume: 39, Issue: 5	2022
Impact of rasagiline nanoparticles on brain targeting efficiency via gellan gum based transdermal patch: A nanotheranostic perspective for Parkinsonism. International journal of biological macromolecules, Dec-01, Volume: 164	2020
Pharmacokinetics, Pharmacodynamics, and Safety of a Single Escalating Dose and Repeated Doses of Rasagiline Transdermal Patch in Healthy Chinese Subjects. Clinical pharmacology in drug development, Volume: 9, Issue: 5	2020
Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease. Neuromolecular medicine, Volume: 21, Issue: 3	2019
Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects. Journal of neural transmission (Vienna, Austria : 1996), Volume: 125, Issue: 11	2018
Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), Volume: 124, Issue: 6	2017
Intensive rehabilitation treatment in early Parkinson's disease: a randomized pilot study with a 2-year follow-up. Neurorehabilitation and neural repair, Volume: 29, Issue: 2	2015
Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, Volume: 29, Issue: 8	2014
Comparative single-dose pharmacokinetics of rasagiline in minipigs after oral dosing or transdermal administration via a newly developed patch. Xenobiotica; the fate of foreign compounds in biological systems, Volume: 43, Issue: 8	2013
LC method for determination of rasagiline mesylate in different plasma matrices and its application to oral pharmacokinetic study in rabbits. Journal of chromatographic science, Volume: 51, Issue: 1	2013
Comparison of oral and transdermal administration of rasagiline mesylate on human melanoma tumor growth in vivo. Cutaneous and ocular toxicology, Volume: 31, Issue: 4	2012
Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease. Drugs, Mar-26, Volume: 72, Issue: 5	2012
Electropharmacograms of rasagiline, its metabolite aminoindan and selegiline in the freely moving rat. Neuropsychobiology, Volume: 62, Issue: 4	2010
The role of rasagiline in the treatment of Parkinson's disease. Clinical interventions in aging, May-25, Volume: 5	2010
Efficacy and tolerability of rasagiline in daily clinical use--a post-marketing observational study in patients with Parkinson's disease. European journal of neurology, Volume: 17, Issue: 9	2010
Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in MPTP-induced parkinsonism. Neuro-degenerative diseases, Volume: 7, Issue: 4	2010
Development and validation of a reverse phase liquid chromatography method for the quantification of rasagiline mesylate in biodegradable PLGA microspheres. Journal of pharmaceutical and biomedical analysis, Jul-12, Volume: 49, Issue: 5	2009
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clinical therapeutics, Volume: 29, Issue: 9	2007
Rasagiline: a review of its use in the management of Parkinson's disease. Drugs, Volume: 67, Issue: 12	2007
Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. The American journal of geriatric pharmacotherapy, Volume: 4, Issue: 4	2006
Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, May-15, Volume: 63, Issue: 10	2006
Rasagiline improves quality of life in patients with early Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, Volume: 21, Issue: 5	2006
Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Drugs of today (Barcelona, Spain : 1998), Volume: 41, Issue: 6	2005
A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Archives of neurology, Volume: 59, Issue: 12	2002
Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. British journal of pharmacology, Volume: 132, Issue: 2	2001
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Effects of rasagiline combined with levodopa and benserazide hydrochloride on motor function and homocysteine and IGF-1 levels in elderly patients with Parkinson's disease. BMC neurology, Oct-06, Volume: 23, Issue: 1	2023
Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. Journal of neurology, Volume: 251, Issue: 9	2004
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

rasagiline

Cross-References

Synonyms (73)

Roles (2)

Drug Classes (3)

Protein Targets (9)

Inhibition Measurements

Biological Processes (46)

Molecular Functions (23)

Ceullar Components (23)

Bioassays (243)

Research

Studies (516)

Study Types

Clinical Trials (56)

Trial Overview

Trial Outcomes

Change From Baseline to Week 12 in Total UMSARS Score for Symptomatic Effect

Change From Baseline to Week 24 in Total Unified Multiple System Atrophy Rating Scale (UMSARS) Score

Change From Baseline to Week 48 or Termination in the Beck Depression Inventory Scale (BDI-II)

Change From Baseline to Week 48 or Termination in the Montreal Cognitive Assessment Scale (MoCA) Scale

Change From Baseline to Week 48/Termination Visit in the Multiple System Atrophy (MSA) Health-related Quality of Life (QoL) Scale

Change From Baseline to Week 48/Termination Visit in the Total Unified Multiple System Atrophy Rating Scale (UMSARS Part I and II)

Clinical Global Impression Improvement (CGI-I) at Week 48/Termination Visit

Estimates for Time to Change in Anti-Parkinsonian or Anti-Orthostatis Hypotension Medications

Mean Score of the Composite Autonomic Symptom Scale Select (COMPASS_Select Change) at Week 48/Termination Visit

Percentage of Participants Who Achieved a Score of >=3 on the Unified Multiple System Atrophy Rating Scale (UMSARS) Question #7 Regarding Ambulation

Rate of Progression in Total Unified Multiple System Atrophy Rating Scale (UMSARS) Score From Baseline to Weeks 12-48

Total Number of Falls During the Study

Change From Baseline to Week 48 or Termination in UMSARS Subscores for Parts I, II and IV

Percentage of Participants Who Achieved a Score of >=3 on the Unified Multiple System Atrophy Rating Scale (UMSARS) Question #1 (Speech Impairment), Question #2 (Swallowing Impairment) and Question #8 (Falling)

Percentage Change From Baseline in Total Epworth Sleepiness Scale (ESS) Score at Week 40

Percentage of Participants With Alanine Aminotransferase (ALT) ≥3 Times Upper Limit of Normal and ≥10% Increase From Baseline

Percentage of Participants With Aspartate Aminotransferase (AST) ≥3 Times Upper Limit of Normal and ≥10% Increase From Baseline

Percentage of Participants With Diastolic Blood Pressure ≥105 mmHg

Percentage of Participants With Suicidality

Percentage of Participants With Systolic Blood Pressure ≥180 mmHg

Becks Depression Inventory (BDI-II)

Fatigue Severity Scale (FSS)

Finger Tapping

Hand-grip Strength

Marin Apathy Inventory (Apathy Evaluation Scale)

Modified Fatigue Impact Scale (MFIS)

Multidimensional Fatigue Inventory (MFIS)

Paced Auditory Serial Addition Test (PASAT)

Parkinson's Disease Sleep Scale (PDSS)

PD Quality of Life Scale (PDQ39)

State-Trait Anxiety Inventory (STAI)

Unified Parkinson's Disease Rating Scale - Motor (UPDRS Part III)

Visual Analog Scale - Subset: Afraid

Visual Analog Scale - Subset: Angry

Visual Analog Scale - Subset: Confused

Visual Analog Scale - Subset: Energetic

Visual Analog Scale - Subset: Happy

Visual Analog Scale - Subset: Sad

Visual Analog Scale - Subset: Tense

Visual Analog Scale - Subset: Tired

Change From Baseline in the Sum of Unified Parkinson's Disease Rating Scale Parts 2 and 3 Scores (UPDRS2+3)

Change From Baseline in the UPDRS Part 2 Score (Activities of Daily Living [ADL])

Number of Participants Who Discontinued Study Due to an AE in Part 1

Number of Participants Who Discontinued Study Due to an AE in Part 2

Number of Participants With Adverse Events (AEs) in Part 1

Number of Participants With Adverse Events (AEs) in Part 2

Percentage of Responders (Participants With a ≥20% Improvement in UPDRS2+3)

CGI-S

PDQ39

Total UPDRS I, II, III Scores

UPDRS ADL (Part II)

UPDRS Motor (Part III)

Change in Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline to Last Observed Value in the Placebo Phase

Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline

Change From Baseline to End of Week 12 Visit in ADL Subscale of PDQ39

Change From Baseline to Week 12 in Total UPDRS II ADL

Change From Baseline to Week 12 in Total UPDRS III Motor

Change in Epworth Sleepiness Scale (ESS) Score.

Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score (Defined as Sum of Parts II and III, Scores (0-160).

"Change From Baseline at Week 12 in Mean On Time Without Troublesome Dyskinesia"

"Change From Baseline in Mean Off Time"

"Percentage of Participants With >30% Change (Reduction) From Baseline at Week 12 in Mean Off Time"

Change From Baseline at Week 12 in Epworth Sleepiness Scale (ESS)